

BMJ Open Does weight management research for adults with severe obesity represent them? Analysis of systematic review data

Clare Robertson , Magaly Aceves-Martins , Moira Cruickshank ,
Mari Imamura , Alison Avenell 

To cite: Robertson C, Aceves-Martins M, Cruickshank M, *et al.* Does weight management research for adults with severe obesity represent them? Analysis of systematic review data. *BMJ Open* 2022;**12**:e054459. doi:10.1136/bmjopen-2021-054459

► Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2021-054459>).

Received 12 June 2021
Accepted 13 May 2022



© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.

Health Services Research Unit, University of Aberdeen, Aberdeen, UK

Correspondence to

Clare Robertson;
c.robertson@abdn.ac.uk

ABSTRACT

Objective Our objective was to determine the extent to which current evidence from long-term randomised controlled trials (RCTs) of weight management is generalisable and applicable to underserved adult groups with obesity (body mass index (BMI) ≥ 35 kg/m²).

Methods Descriptive analysis of 131 RCTs, published after 1990–May 2017 with ≥ 1 year of follow-up, included in a systematic review of long-term weight management interventions for adults with BMI ≥ 35 kg/m² (the REBALANCE Project). Studies were identified from MEDLINE, EMBASE, PsychINFO, SCI, CENTRAL and from hand searching. Reporting of trial inclusion and exclusion criteria, trial recruitment strategies, baseline characteristics and outcomes were analysed using a predefined list of characteristics informed by the PROGRESS (Place of residence, Race/ethnicity/culture/language, Occupation, Gender/sex, Religion, Education, Socioeconomic status, Social capital)-Plus framework and the UK Equality Act 2010.

Results Few (6.1%) trials reported adapting recruitment to appeal to underserved groups. 10.0% reported culturally adapting their trial materials. Only 6.1% of trials gave any justification for their exclusion criteria, yet over half excluded participation for age or mental health reasons. Just over half (58%) of the trials reported participants' race or ethnicity, and one-fifth reported socioeconomic status. Where outcomes were reported for underserved groups, the most common analysis was by sex (47.3%), followed by race or ethnicity (16.8%). 3.1% of trials reported outcomes according to socioeconomic status.

Discussion Although we were limited by poor trial reporting, our results indicate inadequate representation of people most at risk of obesity. Guidance for considering underserved groups may improve the appropriateness of research and inform greater engagement with health and social care services.

Funding National Institute for Health Research Health Technology Assessment Programme (project number: 15/09/04).

PROSPERO registration number CRD42016040190.

BACKGROUND

In high-income countries, and increasingly in low/middle-income countries, lower

STRENGTHS AND LIMITATIONS OF THIS STUDY

- ⇒ A unique analysis exploring whether randomised trials evaluating interventions for weight management for people with severe obesity consider the needs of underserved groups.
- ⇒ Data set includes up-to-date, best available randomised controlled trial evidence (considered to be the highest level of evidence to inform guidelines and clinical practice) identified using robust and exhaustive literature search strategies.
- ⇒ Data set includes wide-ranging weight management interventions delivered in different settings, from an international perspective.
- ⇒ Our analysis was limited by poor reporting of whether subgroup reporting by underserved groups was planned and whether trials were adequately powered to detect subgroup differences.
- ⇒ Non-randomised study designs, interventions with shorter follow-up and unpublished studies may have been more inclusive in their designs and reporting.

incomes, less education, lower socioeconomic status (SES) and disability are associated with greater risk of obesity for adults.^{1–5} While the underlying causes of obesity are varied, there is an increasing association between obesity and deprivation that is driving poorer health outcomes and increasing health inequalities.⁶ For example, most of these risk factors are stronger for women than men,^{1–3 7} although men with obesity may be less likely than women to undertake weight management programmes.⁸ Being an adult with obesity is associated with a lower health-related quality of life than a healthy adult of the same SES.⁹ More severe obesity, such as body mass index (BMI) ≥ 35 kg/m² or more, with its associated greater risks for comorbidities, reduced quality of life and premature mortality,¹⁰ is particularly related to lower SES,^{1 11} and intellectual and physical disabilities.⁴ Poorer outcomes from COVID-19 are also strongly



related to obesity, particularly severe obesity.⁵ For countries such as the USA, UK, Australia and New Zealand, some racial or ethnic groups may also be at much greater risk of obesity, especially severe obesity.^{11–14}

Preventing obesity and providing effective interventions, particularly for people with more severe obesity, are, therefore, a major public health challenge and vital in terms of addressing health inequalities. While organisations such as the US Food and Drug Administration,^{15–18} the National Institutes of Health (NIH)¹⁵ and the National Institute for Health Research (NIHR)¹⁹ have produced guidelines on the inclusion of individuals of all ages, sexes/genders, races and ethnicities, and other physical, sensory/perceptual, cognitive and emotional characteristics, there is a lack of accessible policy-ready evidence on what works in terms of interventions to reduce inequalities in obesity. It is also recognised that some groups (for example, socially disadvantaged, less educated, and minority race or ethnic groups) may be less likely to be recruited into randomised controlled trials (RCTs) for lifestyle interventions.^{20–24} Similarly, religion²⁵ and sexual orientation^{26 27} have been linked to weight and body image. It is, therefore, important to understand the extent to which the current evidence base is applicable to those who are most at risk of experiencing poorer obesity-related health outcomes and have more severe obesity.

This study aimed to determine the extent to which the findings from intervention studies of weight management, as exemplified by long-term RCTs, are generalisable and applicable to those most at risk, particularly underserved groups with severe obesity. To examine these questions, we set out:

1. To describe inclusion and exclusion criteria for RCTs of adult weight management interventions, and in those trials;
2. To describe efforts to tailor recruitment strategies to improve recruitment of people from underserved groups.
3. To describe efforts to culturally adapt interventions to increase the accessibility or appeal to shared characteristics of an underserved group.
4. To describe reported baseline characteristics and outcomes for these groups.

METHODS

Our data set comprised 131 RCTs included in a systematic review of weight management interventions for adults with BMI ≥ 35 kg/m², as part of the REBALANCE Project (REview of Behaviour And Lifestyle interventions for severe obesity: AN evidenCE synthesis; NIHR HTA 15/09/04).¹⁰ BMI ≥ 35 kg/m² was chosen as this is a cut-off often used for accessing bariatric surgery or secondary care weight management clinical services in the UK. Eligible interventions included diet (including, but not limited to, very low-calorie diets and meal replacements), lifestyle (including combination of diet, physical activity and types of counselling), bariatric surgery or orlistat.

RCTs were restricted to publications after 1990 up to May 2017 to reflect more recent clinical practice. Literature searching was conducted in June 2016 and updated in April/May 2017. Details of the literature search method and search strategy are available in the online supplemental files. Trials had to report long-term data on weight change (≥ 1 year of follow-up) and include trial populations with a baseline mean or median BMI ≥ 35 kg/m². The decision to focus on long-term RCTs for this study was informed by the preference for high-quality, long-term evidence of lasting effectiveness in guideline documents^{8 28–31} and are, therefore, most likely to influence treatment policy decisions. Reports published as abstracts or conference proceedings only were excluded. Three reviewers screened titles, abstracts and full-text reports with a 10% quality assessment check. We attempted to contact the first, second and last authors of the main publications to identify all additional materials (ie, protocols, trial materials and diet books) to inform our data extraction for the main REBALANCE report. Full details of the completed REBALANCE Project, including the protocol, have been published.¹⁰

In the absence of definitions of underserved groups, we identified underserved groups by using protected characteristics informed by the PROGRESS (Place of residence, Race/ethnicity/culture/language, Occupation, Gender/sex, Religion, Education, Socioeconomic status, Social capital)-Plus framework³² and the UK Equality Act 2010.³³ Four reviewers (MA-M, MC, MI and CR) conducted double data coding of each RCT for their reporting of whether trials reported details of their inclusion and exclusion criteria, trial recruitment strategies, baseline characteristics and outcome reporting for the following characteristic groups, with disagreements resolved by consensus:

- ▶ Older age
- ▶ Physical health
- ▶ Mental health (including, but not limited to, depression, psychosis, schizophrenia, substance abuse and eating disorders)
- ▶ Comorbidities (eg, types 1 and 2 diabetes mellitus)
- ▶ Gender/sex (including RCTs recruiting only men or women)
- ▶ Sexual orientation
- ▶ Gender reassignment
- ▶ Marriage or civil partnership status
- ▶ Pregnancy
- ▶ Religion or belief
- ▶ Place of residence/housing (including residents of supported accommodation and homeowner status)
- ▶ Race or ethnicity
- ▶ Language
- ▶ Occupational status
- ▶ Education/literacy
- ▶ SES, including individual SES and participants recruited from rural or disadvantaged geographical locations
- ▶ Social capital (including social support networks and/or social isolation)

- ▶ PROGRESS-Plus (personal characteristics associated with discrimination (eg, age, disability), features of relationships (eg, smoking parents, excluded from school), time-dependent relationships (eg, leaving the hospital, respite care, other instances where a person may be temporarily at a disadvantage))

For inclusion and exclusion criteria, trials were coded by predefined categories indicating whether any of the characteristic groups were clearly reported in the inclusion/exclusion criteria, or, where details were not reported, whether the setting of the trial encouraged/discouraged inclusion of individuals from a particular characteristic group (eg, recruitment was set in a health centre predominantly serving people from a characteristic group), or by whether it was unclear that the trial included/excluded people from any of the characteristic groups. For baseline and outcome reporting, we coded whether the protected characteristic was reported and, if reported, whether it was reported for individual treatment groups or the trial population as a whole. Where subgroup analyses were reported, we coded these according to whether it was clear/unclear from the study report that analyses were preplanned. For a trial to be coded as having adapted their recruitment strategy for an underserved group, additional efforts to employ strategies that would appeal to that particular group (eg, held recruitment days in particular settings or developed recruitment materials in multiple languages) had to be demonstrated. Trials that solely recruited from one characteristic group using conventional recruitment methods (eg, newspaper or radio advertisements) were not coded as having an adapted recruitment strategy. Similarly, trials had to demonstrate that their interventions were designed with an underserved group in mind to be coded as having delivered a culturally adapted intervention. The focus of this study was to provide a description of trial methods and trial reporting to answer each of our research questions in relation to underserved groups; therefore, no formal statistical analysis was conducted.

Patient and public involvement

Although we did not consult patient representatives for this particular analysis, three patient representatives were members of the REBALANCE Project Advisory Group, who contributed to developing the research questions, data interpretation and reporting of the research findings.

RESULTS

From the total of 131 included trials, 19 were identified from database searching and 112 were identified from autoalert searching. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow chart and list of included studies are presented in the online supplemental files. Of the 131 trials, 41 (31.3%) provided us with additional materials for their publications for the main REBALANCE report, although most of the information for the current analysis was obtained from the

primary publications. The majority (81 of 131, 61.8%) of included studies were set in North America (80 in the USA and 1 in the USA and Canada), 41 out of 131 (31.3%) were in European countries (including 8 in the UK), 8 (6.1%) were in the Southern Hemisphere (6 in Australia, 1 in New Zealand and 1 in Australia and New Zealand) and 1 in Brazil. None of the trials were set in low-income countries. Just under half (62 of 131, 47.3%) of the studies were published between 2011 and 2017. Five (3.8%) trials were linked to publications reporting qualitative data.^{34–38} Few trials had follow-up duration longer than 12 months, with the exception of the US Look AHEAD trial³⁹ (median duration of 9.6 years), and four trials with follow-up times of 5 years.^{40–43} The Look AHEAD trial was the largest trial, including over 5000 participants. Interventions were wide ranging, including very low calorie (19 of 131, 14.5%), orlistat (12 of 131, 9.2%), bariatric surgery (11 of 131, 8.4%) and other lifestyle weight management programmes incorporating diet and physical activity advice (89 of 131, 67.9%). Details of the characteristics of the included studies can be found in the online supplemental files of the REBALANCE report.¹⁰

Trial recruitment

More than half of the trials (71 of 131, 54%) recruited participants either solely or partially through a health service provider, for example, either solely from outpatient clinics and general practices,^{44 45} or by physician referral and targeted mailing.⁴⁶ Recruitment methods were unclear or not reported in 14 trials (10.7%).^{47–59} Recruitment methods for the other trials were mainly advertisements in local newspapers or other media. Based on their reporting, only three (2.3%) trials were judged to have adapted their recruitment strategies to appeal to underserved groups.^{36 60 61} These preplanned strategies included holding pre-recruitment presentations in US schools,⁶⁰ recruitment events at football stadiums of Scottish Premier League football clubs³⁶ and having bilingual staff take informed consent and provide written consent forms in both English and Spanish languages.⁶¹ It was unclear in a further five (3.8%) trials whether recruitment strategies had been adapted beyond conventional methods.^{53–55 62 63}

Regarding adaptations to interventions, seven trials (5.3%, six from the USA and one from New Zealand)^{61 63–68} recruited participants from diverse racial or ethnic groups and reported cultural adaptations to their interventions. Five (3.8%) of these trials^{63–67} included advice on regional or culturally adapted recipes and foods for specific ethnic groups. Two trials (1.5%)^{61 68} had interventions that were delivered by bilingual staff. One trial⁶⁸ also reported that the intervention was designed for delivery in populations with limited literacy and numeracy and impaired access to health-promoting resources. While two trials^{52 69} recruited participants from workplace settings (an automobile manufacturer and a university; both were not considered to meet the PROGRESS-Plus occupation definition), and

Table 1 The number (and per cent) of trials (n=131) reporting inclusion and exclusion criteria by protected characteristics included in the REBALANCE systematic review of RCTs

	Inclusion			Exclusion
	Protected characteristic is reported in the inclusion criteria, n (%)	Protected characteristic is not reported in inclusion criteria, but an effort was made to recruit from the protected characteristic group, n (%)	Unclear if the protected characteristic was targeted for inclusion or if the trial unintentionally recruited solely/mainly from the protected characteristic group, n (%)	Protected characteristic is reported in the exclusion criteria, or the reported inclusion criteria clearly excluded the protected characteristic, n (%)
Place of residence/housing	5 (3.8)	0	0	0
Race/ethnicity	7 (5.3)	5 (3.8)	2 (1.5)	1 (0.8)
Occupation status	0	0	0	0
Women only	19 (14.5)	0	4 (3.1)	0
Pregnancy	0	0	0	72 (54.9)
Men only	4 (3.0)	0	1 (0.76)	5 (3.8)
Religion/belief	1 (0.8)	0	0	0
Education/literacy	0	0	0	0
Socioeconomic status	3 (2.3)	3 (2.3)	0	0
Marital status	1 (0.8)	0	0	1 (0.8)
Older age	2 (1.5)	1 (0.8)	0	82 (62.6)*
Physical health	10 (7.6)	0	0	51 (38.9)
Diabetes type 1	0	0	0	15 (11.5)
Diabetes type 2	28 (21.4)	0	0	29 (22.1)
Diabetes (type 1 and 2 or type not reported)	0	0	0	3 (2.3)
Mental health	6 (4.6)	0	0	76 (58.0)
Substance abuse	0	0	0	58 (44.2)
Eating disorder	0	0	0	35 (26.7)
Language	0	0	0	16 (12.2)

*Includes eight RCTs recruiting participants up to 75 years, one RCT recruited participants up to 76 years and three RCTs recruited participants aged up to 80 years.
RCTs, randomised controlled trials; REBALANCE, REview of Behaviour And Lifestyle interventions for severe obesity: AN evidenCE synthesis.

one trial recruited married participants,⁷⁰ the trials did not report any attempts to alter their recruitment strategies or interventions to appeal to underserved occupation or social capital groups. The trials did not report recruitment strategies or adaptations to interventions for sexual orientation.

A further five trials (all from the USA)^{71–75} sought recruitment from specific racial or ethnic groups and reported intervention adaptations to increase cultural salience. Four of these trials^{71–74} included culturally specific dietary advice and recipes. One trial described including bilingual interventions⁷¹ and three trials described including interventionists from specific racial or ethnic groups.^{73–75} Two trials^{73 74} described using logos and programme identification ‘for African-Americans’, with one of these trials⁷³ including a video greeting from an African-American principal investigator.

The number of trials reporting inclusion and exclusion criteria by protected characteristic groups is presented in table 1. Four older trials (3.1%)^{47 52 76 77} did not report any inclusion criteria, and inclusion criteria were

unclear in one further study.⁴² Seven (5.3%)^{52 70 78–82} trials did not report any explicit exclusion criteria and did not report that they had no exclusion criteria. Eight (6.1%) trials reported either full^{36 38 45 72 83 84} or partial^{60 85} justification for their exclusion criteria. Justification for exclusion criteria included prevention of poor adherence and losses to follow-up,^{38 45 84 85} such as substance abuse, mental health problems or cognitive impairment (that might, in the opinion of the investigators, hinder participation), lower BMI cut-offs for Asian people,⁶⁰ non-English-language speakers where the intervention required English language comprehension,⁸⁴ influence of pregnancy and breast feeding on weight,⁸⁴ taking medications that influence weight,⁷² and contraindications or safety concerns associated with participating in the intervention (eg, risk of participants with cardiovascular disease participating in exercise programmes).^{36 45 84 85} Over half (58.0%) of the trials reported excluding people with mental health conditions and 44.2% excluded people with substance abuse or addiction issues. The majority of trials also excluded

Table 2 The number (and per cent) of trials (n=131) reporting protected characteristics at baseline in the REBALANCE systematic review of RCTs

	Protected characteristic is reported at baseline for each intervention arm	Protected characteristic is reported at baseline for the whole trial	Total
Age	126 (96.2%)	4 (3.0%)	130 (99.2%)
Physical health	10 (7.6%)	0	10 (7.6%)
Mental health	10 (7.6%)	0	10 (7.6%)
Diabetes	6 (4.6%)	0	6 (4.6%)
Sex	126 (96.2%)	2 (1.5%)	128 (97.7%)
Gender reassignment	0	0	0
Sexual orientation	0	0	0
Marriage/civil partnership status	38 (29.0%)	0	38 (29.0%)
Pregnancy	0	0	0
Place of residence/housing	6 (4.6%)	0	6 (4.6%)
Occupation status	27 (20.6%)	1 (0.8%)	28 (21.4%)
Education/literacy	51 (38.9%)	2 (1.5%)	53 (40.5%)
Socioeconomic status	29 (22.1%)	1 (0.8%)	30 (22.9%)
Social capital	2 (1.5%)	0	2 (1.5%)
Religion/belief	1 (0.8%)	0	1 (0.8%)
Race/ethnicity	74 (56.5%)	2 (1.5%)	76 (58.0%)
PROGRESS-Plus	2 (1.5%)	0	2 (1.5%)

PROGRESS, Place of residence, Race/ethnicity/culture/language, Occupation, Gender/sex, Religion, Education, Socioeconomic status, Social capital; RCTs, randomised controlled trials; REBALANCE, Review of Behaviour And Lifestyle interventions for severe obesity: AN evidenCE synthesis.

adults from older age groups and based on current or planned pregnancy.

Twenty-one (16.0%) trials were judged to have inclusion criteria that might have implicitly excluded certain disadvantaged groups, such as people who do not have healthcare insurance,^{69 86} people who do not belong to a particular religious community group,⁸⁷ people without regular internet³⁵ or telephone⁸⁸ access, and English language comprehension.^{44 45 49 56 60 68 89–96} In a further 40 (30.5%) trials, it was unclear if trial recruitment could have implicitly excluded disadvantaged groups. Few trials reported their inclusion criteria so as to include particular underserved groups or were judged to have made efforts to maximise trial recruitment from these groups. When trial recruitment was targeted, this was usually to recruit women only (19 trials) or people with type 2 diabetes (28 trials).

Reporting of baseline characteristics

Details of the number of trials reporting baseline characteristics of their participants by each of the protected characteristic groups are presented in table 2. The majority of trials reported age (99.2%) and sex (97.7%) in their description of baseline participant characteristics. Just over half of the trials (58.0%) reported race or ethnicity. Education history was less well reported (40.5%). SES was reported by 22.9%, and occupation status by 21.4%. Of the trials that were not specifically for people with diabetes, six (4.6%) included diabetes in their reporting of baseline characteristics. Two (1.5%) trials reported whether

people lived alone or not (coded as social capital).^{97 98} Few trials reported details of the other protected characteristics, and none reported details of gender reassignment, sexual orientation or pregnancy.

Outcome reporting

Details of the number of trials reporting outcomes by each of the protected characteristics are shown in table 3. Very few trials reported outcomes by protected characteristic groups. Where outcomes were reported by protected characteristics, the most common group was sex (47.3%), followed by race or ethnicity (16.8%).

DISCUSSION

Main findings

Our findings demonstrate that most trialists testing weight management strategies to help adults with severe obesity fail to consider populations who are most at risk of poorer health outcomes. Almost all trials were from high-income countries, where lower SES and income are associated with a greater prevalence of obesity, particularly severe obesity.^{1–5} Few trials reported adapting recruitment to appeal to underserved groups or reported culturally adapting their trial materials for ethnic groups or people with limited English language literacy or numeracy. This is concerning as limiting the accessibility or appeal of trials could limit the representativeness of the trial population, and thus limit the generalisability of trial findings. Only 6.1% of trials gave any justification for their exclusion

**Table 3** The number (and per cent) of trials (n=131) reporting outcome data for protected characteristics in the REBALANCE systematic review of RCTs

	Trial recruitment was targeted at people from the protected characteristic group	One or more outcome(s) reported for the protected characteristic in planned subgroup analysis	One or more outcome(s) reported for the protected characteristic – unclear if subgroup analysis was preplanned	Total
Older age	2 (1.5%)*	2 (1.5%)	3 (2.3%)	7 (5.3%)
Physical health	10 (7.6%)	0	0	10 (7.6%)
Mental health	6 (4.6%)	0	2 (1.5%)	8 (6.1%)
Diabetes	28 (21.3%)	0	1 (0.8%)	29 (22.1%)
Sex	23 (17.5%)†	17 (13.0%)	22 (16.8%)	62 (47.3%)
Gender reassignment	0	0	0	0
Sexual orientation	0	0	0	0
Marriage/civil partnership status	1 (0.8%)	1 (0.8%)	3 (2.3%)	5 (3.8%)
Pregnancy	0	0	0	0
Place of residence/housing	0	2 (1.5%)	0	2 (1.5%)
Occupation status	2 (1.5%)	2 (1.5%)	4 (3.1%)	8 (6.1%)
Education/literacy	0	1 (0.8%)	6 (4.6%)	7 (5.3%)
Socioeconomic status	5 (3.8%)	4 (3.1%)	3 (2.3%)	12 (9.2%)
Social capital	1 (0.8%)	3 (2.3%)	2 (1.5%)	6 (4.6%)
Religion/belief	1 (0.8%)	0	0	1 (0.8%)
Race/ethnicity	8 (6.1%)	5 (3.8%)	9 (6.9%)	22 (16.8%)
PROGRESS-Plus	0	0	0	0

*Both trials recruited participants aged ≥ 65 years.

†Nineteen women-only trials, four men-only trials.

PROGRESS, Place of residence, Race/ethnicity/culture/language, Occupation, Gender/sex, Religion, Education, Socioeconomic status, Social capital; RCTs, randomised controlled trials; REBALANCE, Review of Behaviour And Lifestyle interventions for severe obesity: AN evidenCE synthesis.

criteria, yet more than half excluded participation for age or mental health reasons. Where justification for exclusion was reported, the rationale included excluding people who were deemed likely to have poor intervention adherence or were more likely to be lost to follow-up, such as people with substance abuse, cognitive impairment or mental health problems. Excluding these groups could lead to an unrealistic estimation of the real-world effectiveness of interventions. Just over half of the trials reported participants' race or ethnicity, and only around one-fifth reported SES. Where outcomes were reported for underserved groups, the most common analysis was by sex (47.3%), followed by race or ethnicity (16.8%); however, where analyses were presented as subgroups, it was often unclear whether these analyses were planned or unplanned. Similarly, some smaller trials might have been underpowered to detect differences in treatment effects between subgroups, but this was also unclear from trial reporting. This finding was also demonstrated by Liu and colleagues,⁹⁹ who highlighted a lack of transparent reporting of intentions to analyse race and ethnicity subgroups in Cochrane intervention reviews. Only 3.1% of the trials we reviewed reported outcomes according to SES. Few trials reported outcomes by the other protected characteristics.

Although we were limited by the available information in the published reports, our findings are concerning. In almost all trials, it is difficult to assess the generalisability of findings to the wider population of adults with severe obesity. There is clear evidence^{1-5 11 12} that underserved groups with lower incomes, less education, lower SES, intellectual and physical disabilities, or poorer mental health are more at risk of obesity, particularly severe obesity, in high-income countries, especially the USA which provided the majority of trials examined. We do not have relevant data to be able to comment on the reasons for poor reporting. Nevertheless, the lack of reporting for characteristics reflecting underserved groups suggests that trial investigators did not consider or faced barriers that prevented their inclusion in the design, recruitment, and analysis or reporting of their interventions.

Our finding that few trials adapted their recruitment methods or interventions to appeal to underserved groups suggests lack of engagement with underserved people with obesity in the design of services. This is important, given that a systematic review of qualitative research by Sutcliffe and colleagues¹⁰⁰ showed how service users have perspectives that should inform weight management services to improve their reach. From systematic reviews, researchers have clearly demonstrated the need

to involve communities in all stages of research in order to enhance the engagement and generalisability of that research, acknowledging that this requires extended time frames and greater costs.^{21 101} For example, Ni She and colleagues¹⁰² undertook a rapid realist review of the mechanisms and resources needed to engage underserved, seldom-heard groups in health and social care research, with items grouped by an expert panel under the headings of environmental and social planning, service provision, guidelines, fiscal measures, communication and marketing, and regulation and legislation. In the USA, Arnegard and colleagues¹⁰³ have also called on the NIH's stakeholder groups to redouble their efforts to encourage sex/gender-aware reporting of biomedical investigations. We endorse this call following the findings from our previous systematic review of weight management interventions for men with obesity.⁸ Our review highlighted the paucity of evidence for men, who are less likely to take part in weight management interventions, and the lack of engagement of men in all aspects of intervention design, and optimal trial recruitment processes of weight management.⁸

While the reasons for the under-representation of underserved groups in RCTs are likely to be complex and multifaceted, with many known and unknown barriers to participation, there is evidence that, for some groups, willingness to participate is not a predominant factor.¹⁰⁴ Mindful of the need to improve the engagement of underserved groups in research in the UK, the NIHR set up the INCLUDE Project,¹⁹ which has led to the INCLUDE ethnicity framework¹⁰⁵; providing four key questions on who should be involved in research, and how to facilitate involvement. Others have investigated and found a lack of external validity in trials for people with asthma,¹⁰⁶ type 2 diabetes^{107 108} and neurological disease,¹⁰⁹ or a failure to justify exclusion criteria in trials of cardiovascular disease prevention¹¹⁰ other than for safety reasons. These publications did not consider the SES or educational attainment of trial participants. In a systematic review of 305 trials of clinical conditions, He and colleagues¹¹¹ found high exclusion rates in trials for people with hypertension (83.0%), lipid-lowering drugs in primary prevention (85.9%), type 2 diabetes (81.7%), chronic obstructive pulmonary disorder (COPD) (84.3%) and asthma (96.0%), with no strong evidence that exclusion rates had changed with time.

More recently, others have also highlighted the small number of intervention studies testing out weight management for underserved adults,¹¹² or policies to assist socioeconomically disadvantaged groups.¹¹³ A 2015 systematic review of interventions aimed at reducing socioeconomic inequalities for adults with obesity¹¹⁴ found that primary care-delivered tailored weight loss programmes and group weight loss interventions had the most evidence of potential effectiveness in reducing obesity, at least in the short term, among low-income women, but there were few individual-level intervention studies and a lack of long-term evidence of effectiveness.

Strengths and limitations

We used categories informed by the PROGRESS-Plus framework³² and the UK Equality Act 2010³³ as the key characteristics for identifying those underserved participants who should be considered for study design, public-patient involvement, recruitment, analysis and reporting, not just for trials of weight management, but trials generally. O'Neill and colleagues³² have shown how the prior PROGRESS framework can be used as an equity lens for systematic reviews and methodological studies; however, NIHR's INCLUDE Project has recently published a more extensive list of categories of underserved groups to consider with regard to representation in trials.¹¹⁵

Our literature search attempted to identify all long-term randomised trials published since 1990 for adults with BMI ≥ 35 kg/m² irrespective of the type of lifestyle intervention, including comparisons with orlistat and bariatric surgery. Although we included publications in any language from any country, we cannot exclude the possibility that we failed to find some trials, particularly those from low-income countries, which might not be listed in the databases we searched.

While we originally contacted authors for all available additional materials relating to our main research question for the REBALANCE Project,¹⁰ we did not recontact authors to obtain additional information relating to the current analysis. We were also limited by poor reporting by trial authors. Some trials were statistically underpowered to detect subgroup differences, and this might explain under-reporting of underserved characteristics; however, this was unclear from the trial reports. It is also possible that some trialists were unable to obtain relevant baseline data for some underserved groups if this was deemed sensitive by an ethics committee, for example, sexual orientation. Nevertheless, we consider that most characteristics are pivotal to interpreting these trials into real-world guidance and services, so we would expect their presentation in trial publications, especially at baseline. We assessed long-term RCT evidence because it is most likely to inform guidance on weight management.²⁸⁻³¹ Other study designs, interventions with shorter follow-up and unpublished studies may have been more inclusive in their designs and reporting.

Recommendations for research

Trialists should improve reporting of their justification of inclusion and exclusion criteria to meet current Consolidated Standards of Reporting Trials (CONSORT) statement guidelines,¹¹⁶ and report sufficient data to allow comparisons between their populations and the populations for whom the interventions apply. Including core criteria for baseline reporting within the CONSORT checklist¹¹⁶ could help to improve the completeness of reporting of these factors. NIHR's INCLUDE Project's ethnicity framework provides important factors to consider with regard to ethnic groups (<https://www.trialforge.org/trial-forge-centre/include/>), which can help provide transferable considerations for other underserved

groups. However, a wider equity lens may be needed in the face of groups with multiple disadvantages. Although guidance for research will aid considerations of equity, we do not yet have ways of assessing when proportional representation in larger trials and subgroup reporting for underserved groups is insufficient. This research should be explicitly conducted with and for these underserved groups, ensuring user involvement in all stages of the research process.

CONCLUSIONS AND RECOMMENDATIONS FOR PRACTICE

Long-term RCTs of weight management in people with BMI ≥ 35 kg/m² have inadequate representation of and engagement with underserved groups, who are particularly relevant for health and social care services. Thus, guidance for weight management research on how to improve the representation of underserved groups in clinical trials may improve the appropriateness of that research and help inform greater engagement of underserved communities with health and social care services.

Acknowledgements We thank the members of the REBALANCE Project and Advisory Groups for their contributions to the REBALANCE Project. We thank Shaun Trewick and Heidi Gardner, Health Services Research Unit, University of Aberdeen, for helpful discussions on trial generalisability and inclusion of underserved groups.

Contributors CR, MA-M, MC, MI and AA contributed to conception and design, acquisition of data, or analysis and interpretation of data, and revised data critically for important intellectual content of this manuscript. All authors critically reviewed the manuscript and approved the final version submitted for publication. CR takes responsibility for the integrity of the data and the accuracy of the data analysis. CR is the guarantor and accepts full responsibility for the finished work and/or the conduct of the study, had access to the data, and controlled the decision to publish.

Funding The REBALANCE Study was funded by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (project number: 15/09/04).

Disclaimer The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. The Health Services Research Unit is funded by the Chief Scientist Office of the Scottish Government Health and Social Care Directorates.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not required.

Ethics approval Ethical approval was not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request. All data relevant to the study are included in the article, uploaded as supplemental information, or are available from the NIHR journals library (REBALANCE) REview of Behaviour And Lifestyle interventions for severe obesity: AN evidenCE synthesis (nihr.ac.uk)

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits

others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: <https://creativecommons.org/licenses/by/4.0/>.

ORCID iDs

Clare Robertson <http://orcid.org/0000-0001-6019-6795>
Magaly Aceves-Martins <http://orcid.org/0000-0002-9441-142X>
Moira Cruickshank <http://orcid.org/0000-0002-5182-884X>
Mari Imamura <http://orcid.org/0000-0003-4871-0354>
Alison Avenell <http://orcid.org/0000-0003-4813-5628>

REFERENCES

- Booth HP, Charlton J, Gulliford MC. Socioeconomic inequality in morbid obesity with body mass index more than 40 kg/m² in the United States and England. *SSM Popul Health* 2017;3:172–8.
- Devaux M, Sassi F. Social inequalities in obesity and overweight in 11 OECD countries. *Eur J Public Health* 2013;23:464–9.
- El-Sayed AM, Scarborough P, Galea S. Unevenly distributed: a systematic review of the health literature about socioeconomic inequalities in adult obesity in the United Kingdom. *BMC Public Health* 2012;12:18.
- Hsieh K, Rimmer JH, Heller T. Obesity and associated factors in adults with intellectual disability. *J Intellect Disabil Res* 2014;58:851–63.
- Public Health England. Excess Weight and COVID-19: Insights from new evidence [Internet]. London: PHE publications, 2021. Available: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/907966/PHE_insight_Excess_weight_and_COVID-19_FINAL.pdf
- Holmes J. *Tackling obesity: the role of the NHS in a whole-system approach*. London: The Kings Fund, 2021.
- Grech A, Allman-Farinelli M. Prevalence and period trends of overweight and obesity in Australian young adults. *Eur J Clin Nutr* 2016;70:1083–5.
- Robertson C, Archibald D, Avenell A, et al. Systematic reviews of and integrated report on the quantitative, qualitative and economic evidence base for the management of obesity in men. *Health Technol Assess* 2014;18:v-vi, xxiii-xxix, 1-424.
- Minet Kinge J, Morris S. Socioeconomic variation in the impact of obesity on health-related quality of life. *Soc Sci Med* 2010;71:1864–71.
- Avenell A, Robertson C, Skea Z, et al. Bariatric surgery, lifestyle interventions and orlistat for severe obesity: the REBALANCE mixed-methods systematic review and economic evaluation. *Health Technol Assess* 2018;22:1-246.
- Green MA, Rowe F. Explaining the widening distribution of body mass index: a decomposition analysis of trends for England, 2002–2004 and 2012–2014. *Area* 2020;1–11.
- Ogden CL, Fryar CD, Martin CB, et al. Trends in obesity prevalence by race and Hispanic Origin—1999–2000 to 2017–2018. *JAMA* 2020;324:1208–10.
- Menigoz K, Nathan A, Turrell G. Ethnic differences in overweight and obesity and the influence of acculturation on immigrant bodyweight: evidence from a national sample of Australian adults. *BMC Public Health* 2016;16:932.
- New Zealand Ministry of Health. Obesity statistics, 2020. Available: <https://www.health.govt.nz/nz-health-statistics/health-statistics-and-data-sets/obesity-statistics> [Accessed Oct 2021].
- U.S. Food and Drug Administration (FDA). Guidance for industry: collection of race and ethnicity data in clinical trials. Available: <https://www.fda.gov/media/75453/download> [Accessed Mar 2021].
- U.S. Food and Drug Administration (FDA). Evaluation and reporting of age-, race-, and ethnicity-specific data in medical device clinical studies. Available: <https://www.fda.gov/media/98686/download> [Accessed Mar 2021].
- U.S. Food and Drug Administration (FDA). Design considerations for devices intended for home use. Available: <https://www.fda.gov/media/84830/download> [Accessed Mar 2021].
- National Institutes of Health [internet]. U.S. 2019. Inclusion policies for research involving human subjects. Available: <https://grants.nih.gov/policy/inclusion.htm> [Accessed Mar 2021].
- National Institute for Health Research [Internet]. London: The Institute; 2020 [cited February 2021]. Improving inclusion of under-served groups in clinical research: Guidance from the NIHR INCLUDE project. Available: www.nihr.ac.uk/documents/improving-

- inclusion-of-under-served-groups-in-clinical-research-guidance-from-include-project/25435
- 20 Unger JM, Gralow JR, Albain KS, *et al*. Patient income level and cancer clinical trial participation: a prospective survey study. *JAMA Oncol* 2016;2:137–9.
 - 21 Bonevski B, Randell M, Paul C, *et al*. Reaching the hard-to-reach: a systematic review of strategies for improving health and medical research with socially disadvantaged groups. *BMC Med Res Methodol* 2014;14:42.
 - 22 Sateren WB, Trimble EL, Abrams J, *et al*. How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials. *J Clin Oncol* 2002;20:2109–17.
 - 23 Smart A, Harrison E. The under-representation of minority ethnic groups in UK medical research. *Ethn Health* 2017;22:65–82.
 - 24 Sardar MR, Badri M, Prince CT, *et al*. Underrepresentation of women, elderly patients, and racial minorities in the randomized trials used for cardiovascular guidelines. *JAMA Intern Med* 2014;174:1868–70.
 - 25 Yeary KH-CK, Sobal J, Wethington E. Religion and body weight: a review of quantitative studies. *Obes Rev* 2017;18:1210–122.
 - 26 de Souza P, Ciclitira KE, Men CKE. Men and dieting: a qualitative analysis. *J Health Psychol* 2005;10:793–804.
 - 27 Gough B, Flanders G. Celebrating "obese" bodies: Gay "bears" talk about weight, body image and health. *Int J Mens Health* 2009;8:235–53.
 - 28 National Institute for Health and Care Excellence. Weight management: lifestyle services for overweight or obese adults. London; NICE 2014. Available: <https://www.nice.org.uk/guidance/ph53> [Accessed May 2021].
 - 29 National Health and Medical Research Council. *Clinical practice guidelines for the management of overweight and obesity in adults, adolescents and children in Australia*. Melbourne: National Health and Medical Research Council, 2013.
 - 30 Hartmann-Boyce J, Johns D, Aveyard P. *Managing overweight and obese adults: update review. The clinical effectiveness of long-term weight management schemes for adults: review 1A*. Oxford: University of Oxford, 2013. <https://www.nice.org.uk/guidance/ph53/evidence/evidence-review-1a-431707933> (accessed May 2021)
 - 31 Hartmann-Boyce J, Johns D, Aveyard P. *How components of behavioural weight management programmes affect weight change: review 1B*. Oxford: University of Oxford, 2013. <https://www.nice.org.uk/guidance/ph53/evidence/evidence-review-1b-431707934> (accessed May 2021)
 - 32 O'Neill J, Tabish H, Welch V, *et al*. Applying an equity lens to interventions: using progress ensures consideration of socially stratifying factors to illuminate inequities in health. *J Clin Epidemiol* 2014;67:56–64.
 - 33 Government Equalities Office, Equality and Human Rights Commission [Internet]. London: Government Digital Service; 2013 [cited February 2021]. Equality Act 2010: guidance. Available: <https://www.gov.uk/guidance/equality-act-2010-guidance>
 - 34 Yeh M-C, Rodriguez E, Nawaz H, *et al*. Technical skills for weight loss: 2-y follow-up results of a randomized trial. *Int J Obes Relat Metab Disord* 2003;27:1500–6.
 - 35 Little P, Stuart B, Hobbs FDR, *et al*. Randomised controlled trial and economic analysis of an Internet-based weight management programme: POWeR+ (positive online weight reduction). *Health Technol Assess* 2017;21:1–62.
 - 36 Hunt K, Gray CM, Maclean A, *et al*. Do weight management programmes delivered at professional football clubs attract and engage high risk men? A mixed-methods study. *BMC Public Health* 2014;14:50.
 - 37 McRobbie H, Hajek P, Peerbux S, *et al*. Tackling obesity in areas of high social deprivation: clinical effectiveness and cost-effectiveness of a task-based weight management group programme - a randomised controlled trial and economic evaluation. *Health Technol Assess* 2016;20:1–150.
 - 38 Green CA, Yarborough BJH, Leo MC, *et al*. Weight maintenance following the STRIDE lifestyle intervention for individuals taking antipsychotic medications. *Obesity* 2015;23:1995–2001.
 - 39 Look AHEAD Research Group, Wing RR, Bolin P, *et al*. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. *N Engl J Med* 2013;369:145–54.
 - 40 Hakala P, Karvetti RL, Rönnemaa T. Group vs. individual weight reduction programmes in the treatment of severe obesity—a five year follow-up study. *Int J Obes Relat Metab Disord* 1993;17:97–102.
 - 41 Hakala P. Weight reduction programmes at a rehabilitation centre and a health centre based on group counselling and individual support: short- and long-term follow-up study. *Int J Obes Relat Metab Disord* 1994;18:483–9.
 - 42 Mingrone G, Greco AV, Giancaterini A, *et al*. Sex hormone-binding globulin levels and cardiovascular risk factors in morbidly obese subjects before and after weight reduction induced by diet or malabsorptive surgery. *Atherosclerosis* 2002;161:455–62.
 - 43 Schauer PR, Kashyap SR, Wolski K, *et al*. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. *N Engl J Med* 2012;366:1567–76.
 - 44 Bliddal H, Leeds AR, Stigsgaard L, *et al*. Weight loss as treatment for knee osteoarthritis symptoms in obese patients: 1-year results from a randomised controlled trial. *Ann Rheum Dis* 2011;70:1798–803.
 - 45 Azar KMJ, Xiao L, Ma J. Baseline obesity status modifies effectiveness of adapted diabetes prevention program lifestyle interventions for weight management in primary care. *Biomed Res Int* 2013;2013:191209.
 - 46 Appel LJ, Clark JM, Yeh H-C, *et al*. Comparative effectiveness of weight-loss interventions in clinical practice. *N Engl J Med* 2011;365:1959–68.
 - 47 Agras WS, Berkowitz RI, Arnow BA, *et al*. Maintenance following a very-low-calorie diet. *J Consult Clin Psychol* 1996;64:610–3.
 - 48 Bakris G, Calhoun D, Egan B, *et al*. Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. *J Hypertens* 2002;20:2257–67.
 - 49 Bartels SJ, Pratt SI, Aschbrenner KA, *et al*. Clinically significant improved fitness and weight loss among overweight persons with serious mental illness. *Psychiatr Serv* 2013;64:729–36.
 - 50 Brehm BJ, Lattin BL, Summer SS, *et al*. One-year comparison of a high-monounsaturated fat diet with a high-carbohydrate diet in type 2 diabetes. *Diabetes Care* 2009;32:215–20.
 - 51 Broom I, Wilding J, Stott P, *et al*. Randomised trial of the effect of orlistat on body weight and cardiovascular disease risk profile in obese patients: UK multimorbidity study. *Int J Clin Pract* 2002;56:494–9.
 - 52 Dennison KF, Galante D, Dennison D, *et al*. A one year Post-Program assessment of a computer-assisted instruction (CAI) weight management program for industrial employees: lessons learned. *J Health Educ* 1996;27:38–42.
 - 53 Hauptman J, Lucas C, Boldrin MN, *et al*. Orlistat in the long-term treatment of obesity in primary care settings. *Arch Fam Med* 2000;9:160–7.
 - 54 Kahleová H, Hill M, Pelikánová T. Vegetarian vs. conventional diabetic diet - A 1-year follow-up. *Cor Vasa* 2014;56:e140–4.
 - 55 Kelley DE, Bray GA, Pi-Sunyer FX, *et al*. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: a 1-year randomized controlled trial. *Diabetes Care* 2002;25:1033–41.
 - 56 Ströbl V, Knisel W, Landgraf U, *et al*. A combined planning and telephone aftercare intervention for obese patients: effects on physical activity and body weight after one year. *J Rehabil Med* 2013;45:198–205.
 - 57 Swinburn BA, Carey D, Hills AP, *et al*. Effect of orlistat on cardiovascular disease risk in obese adults. *Diabetes Obes Metab* 2005;7:254–62.
 - 58 Wadden TA, Volger S, Sarwer DB, *et al*. A two-year randomized trial of obesity treatment in primary care practice. *N Engl J Med* 2011;365:1969–79.
 - 59 Wing RR, Marcus MD, Salata R, *et al*. Effects of a very-low-calorie diet on long-term glycemic control in obese type 2 diabetic subjects. *Arch Intern Med* 1991;151:1334–40.
 - 60 Berry DC, Schwartz TA, McMurray RG, *et al*. The family partners for health study: a cluster randomized controlled trial for child and parent weight management. *Nutr Diabetes* 2014;4:e101.
 - 61 Van Name MA, Camp AW, Magenheimer EA, *et al*. Effective translation of an intensive lifestyle intervention for Hispanic women with prediabetes in a community health center setting. *Diabetes Care* 2016;39:525–31.
 - 62 Khoo J, Piantadosi C, Duncan R, *et al*. Comparing effects of a low-energy diet and a high-protein low-fat diet on sexual and endothelial function, urinary tract symptoms, and inflammation in obese diabetic men. *J Sex Med* 2011;8:2868–75.
 - 63 Kumanyika SK, Fassbender JE, Sarwer DB, *et al*. One-Year results of the Think Health! study of weight management in primary care practices. *Obesity* 2012;20:1249–57.
 - 64 Krebs JD, Elley CR, Parry-Strong A, *et al*. The Diabetes Excess Weight Loss (DEWL) trial: a randomised controlled trial of high-protein versus high-carbohydrate diets over 2 years in type 2 diabetes. *Diabetologia* 2012;55:905–14.
 - 65 Mayer-Davis EJ, D'Antonio AM, Smith SM, *et al*. Pounds off with empowerment (POWER): a clinical trial of weight management

- strategies for black and white adults with diabetes who live in medically underserved rural communities. *Am J Public Health* 2004;94:1736–42.
- 66 Perri MG, Limacher MC, Durning PE, *et al.* Extended-care programs for weight management in rural communities: the treatment of obesity in underserved rural settings (TOURS) randomized trial. *Arch Intern Med* 2008;168:2347–54.
- 67 Perri MG, Limacher MC, von Castel-Roberts K, *et al.* Comparative effectiveness of three doses of weight-loss counseling: two-year findings from the rural LITE trial. *Obesity* 2014;22:2293–300.
- 68 Bennett GG, Warner ET, Glasgow RE, *et al.* Obesity treatment for socioeconomically disadvantaged patients in primary care practice. *Arch Intern Med* 2012;172:565–74.
- 69 Østbye T, Stroo M, Brouwer RJN, *et al.* Steps to Health employee weight management randomized control trial: short-term follow-up results. *J Occup Environ Med* 2015;57:188–95.
- 70 Wing RR, Marcus MD, Epstein LH, *et al.* A "family-based" approach to the treatment of obese type II diabetic patients. *J Consult Clin Psychol* 1991;59:156–62.
- 71 Poston WSC, Reeves RS, Haddock CK, *et al.* Weight loss in obese Mexican Americans treated for 1-year with orlistat and lifestyle modification. *Int J Obes Relat Metab Disord* 2003;27:1486–93.
- 72 Martin PD, Dutton GR, Rhode PC, *et al.* Weight loss maintenance following a primary care intervention for low-income minority women. *Obesity* 2008;16:2462–7.
- 73 Kumanyika SK, Shults J, Fassbender J, *et al.* Outpatient weight management in African-Americans: the Healthy Eating and Lifestyle Program (HELP) study. *Prev Med* 2005;41:488–502.
- 74 Kumanyika SK, Wadden TA, Shults J, *et al.* Trial of family and friend support for weight loss in African American adults. *Arch Intern Med* 2009;169:1795–804.
- 75 Fitzgibbon ML, Stolley MR, Schiffer L, *et al.* Obesity Reduction Black Intervention Trial (ORBIT): 18-month results. *Obesity* 2010;18:2317–25.
- 76 Wadden TA, Berkowitz RI, Vogt RA, *et al.* Lifestyle modification in the pharmacologic treatment of obesity: a pilot investigation of a potential primary care approach. *Obes Res* 1997;5:218–26.
- 77 Wadden TA, Vogt RA, Foster GD, *et al.* Exercise and the maintenance of weight loss: 1-year follow-up of a controlled clinical trial. *J Consult Clin Psychol* 1998;66:429–33.
- 78 Torgerson JS, Lissner L, Lindroos AK, *et al.* VLCD plus dietary and behavioural support versus support alone in the treatment of severe obesity. A randomised two-year clinical trial. *Int J Obes Relat Metab Disord* 1997;21:987–94.
- 79 Melin I, Karlström B, Lappalainen R, *et al.* A programme of behaviour modification and nutrition counselling in the treatment of obesity: a randomised 2-y clinical trial. *Int J Obes Relat Metab Disord* 2003;27:1127–35.
- 80 Pascale RW, Wing RR, Butler BA, *et al.* Effects of a behavioral weight loss program stressing calorie restriction versus calorie plus fat restriction in obese individuals with NIDDM or a family history of diabetes. *Diabetes Care* 1995;18:1241–8.
- 81 Perri MG, Nezu AM, McKelvey WF, *et al.* Relapse prevention training and problem-solving therapy in the long-term management of obesity. *J Consult Clin Psychol* 2001;69:722–6.
- 82 Richelsen B, Tonstad S, Rössner S, *et al.* Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study. *Diabetes Care* 2007;30:27–32.
- 83 Cummings DE, Arterburn DE, Westbrook EO, *et al.* Gastric bypass surgery vs intensive lifestyle and medical intervention for type 2 diabetes: the CROSSROADS randomised controlled trial. *Diabetologia* 2016;59:945–53.
- 84 Daubenmier J, Moran PJ, Kristeller J, *et al.* Effects of a mindfulness-based weight loss intervention in adults with obesity: a randomized clinical trial. *Obesity* 2016;24:794–804.
- 85 Dixon JB, Schachter LM, O'Brien PE, *et al.* Surgical vs conventional therapy for weight loss treatment of obstructive sleep apnea: a randomized controlled trial. *JAMA* 2012;308:1142–9.
- 86 Dutton GR, Nackers LM, Dubyak PJ, *et al.* A randomized trial comparing weight loss treatment delivered in large versus small groups. *Int J Behav Nutr Phys Act* 2014;11:123.
- 87 Latner JD, Ciao AC, Wendicke AU, *et al.* Community-Based behavioral weight-loss treatment: long-term maintenance of weight loss, physiological, and psychological outcomes. *Behav Res Ther* 2013;51:451–9.
- 88 Lowe MR, Butryn ML, Thomas JG, *et al.* Meal replacements, reduced energy density eating, and weight loss maintenance in primary care patients: a randomized controlled trial. *Obesity* 2014;22:94–100.
- 89 Christensen P, Frederiksen R, Bliddal H, *et al.* Comparison of three weight maintenance programs on cardiovascular risk, bone and vitamins in sedentary older adults. *Obesity* 2013;21:1982–90.
- 90 Damschroder LJ, Lutes LD, Kirsh S, *et al.* Small-changes obesity treatment among veterans: 12-month outcomes. *Am J Prev Med* 2014;47:541–53.
- 91 Eaton CB, Hartman SJ, Perzanowski E, *et al.* A randomized clinical trial of a tailored lifestyle intervention for obese, sedentary, primary care patients. *Ann Fam Med* 2016;14:311–9.
- 92 Wolf AM, Conaway MR, Crowther JQ, *et al.* Translating lifestyle intervention to practice in obese patients with type 2 diabetes: improving control with activity and nutrition (ICAN) study. *Diabetes Care* 2004;27:1570–6.
- 93 Mensinger JL, Calogero RM, Stranges S, *et al.* A weight-neutral versus weight-loss approach for health promotion in women with high BMI: a randomized-controlled trial. *Appetite* 2016;105:364–74.
- 94 Nackers LM, Middleton KR, Dubyak PJ, *et al.* Effects of prescribing 1,000 versus 1,500 kilocalories per day in the behavioral treatment of obesity: a randomized trial. *Obesity* 2013;21:2481–7.
- 95 Nilsen V, Bakke PS, Gallefoss F. Effects of lifestyle intervention in persons at risk for type 2 diabetes mellitus - results from a randomised, controlled trial. *BMC Public Health* 2011;11:893.
- 96 O'Neil PM, Miller-Kovach K, Tuerk PW, *et al.* Randomized controlled trial of a nationally available weight control program tailored for adults with type 2 diabetes. *Obesity* 2016;24:2269–77.
- 97 Djuric Z, Mirasolo J, Kimbrough L, *et al.* A pilot trial of spirituality counseling for weight loss maintenance in African American breast cancer survivors. *J Natl Med Assoc* 2009;101:552–64.
- 98 Reichard A, Saunders MD, Saunders RR, *et al.* A comparison of two weight management programs for adults with mobility impairments. *Disabil Health J* 2015;8:61–9.
- 99 Liu P, Ross JS, Ioannidis JP, *et al.* Prevalence and significance of race and ethnicity subgroup analyses in Cochrane intervention reviews. *Clin Trials* 2020;17:231–4.
- 100 Sutcliffe K, Melendez-Torres GJ, Burchett HED, *et al.* The importance of service-users' perspectives: a systematic review of qualitative evidence reveals overlooked critical features of weight management programmes. *Health Expect* 2018;21:563–73.
- 101 De las Nueces D, Hacker K, DiGirolamo A, *et al.* A systematic review of community-based participatory research to enhance clinical trials in racial and ethnic minority groups. *Health Serv Res* 2012;47:1363–86.
- 102 Ni Shé É, Morton S, Lambert V, *et al.* Clarifying the mechanisms and resources that enable the reciprocal involvement of seldom heard groups in health and social care research: a collaborative rapid realist review process. *Health Expect* 2019;22:298–306.
- 103 Arnegard ME, Whitten LA, Hunter C, *et al.* Sex as a biological variable: a 5-year progress report and call to action. *J Womens Health* 2020;29:858–64.
- 104 Wendler D, Kington R, Madans J, *et al.* Are racial and ethnic minorities less willing to participate in health research? *PLoS Med* 2006;3:e19.
- 105 Trial Forge [Internet]. Aberdeen, Scotland: Trial Forge; 2020 [cited February 2021]. The INCLUDE ethnicity framework. Available: <https://www.trialforge.org/trial-forge-centre/include/>
- 106 Travers J, Marsh S, Williams M, *et al.* External validity of randomised controlled trials in asthma: to whom do the results of the trials apply? *Thorax* 2007;62:219–23.
- 107 Saunders C, Byrne CD, Guthrie B, *et al.* External validity of randomized controlled trials of glycaemic control and vascular disease: how representative are participants? *Diabet Med* 2013;30:300–8.
- 108 Hoppe C, Kerr D. Minority underrepresentation in cardiovascular outcome trials for type 2 diabetes. *Lancet Diabetes Endocrinol* 2017;5:13.
- 109 Trivedi RB, Humphreys K. Participant exclusion criteria in treatment research on neurological disorders: are unrepresentative study samples problematic? *Contemp Clin Trials* 2015;44:20–5.
- 110 Schmidt AF, Groenwold RHH, van Delden JJM, *et al.* Justification of exclusion criteria was underreported in a review of cardiovascular trials. *J Clin Epidemiol* 2014;67:635–44.
- 111 He J, Morales DR, Guthrie B. Exclusion rates in randomized controlled trials of treatments for physical conditions: a systematic review. *Trials* 2020;21:228.
- 112 Hayba N, Partridge SR, Nour MM, *et al.* Effectiveness of lifestyle interventions for preventing harmful weight gain among young adults from lower socioeconomic status and ethnically diverse backgrounds: a systematic review. *Obes Rev* 2018;19:333–46.
- 113 Olstad DL, Ancilotto R, Teychenne M, *et al.* Can targeted policies reduce obesity and improve obesity-related behaviours in

- socioeconomically disadvantaged populations? A systematic review. *Obes Rev* 2017;18:791–807.
- 114 Bambra CL, Hillier FC, Cairns J-M, *et al.* How effective are interventions at reducing socioeconomic inequalities in obesity among children and adults? two systematic reviews. *Public Health Res* 2015;3:1–446.
- 115 Witham MD, Anderson E, Carroll C, *et al.* Developing a roadmap to improve trial delivery for under-served groups: results from a UK multi-stakeholder process. *Trials* 2020;21:694.
- 116 Moher D, Hopewell S, Schulz KF, *et al.* Consort 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. *BMJ* 2010;340:c869.

Appendix 1 Literature search strategies

Literature searching was conducted in June 2016 and updated in April/May 2017. The following databases were searched without language restriction: MEDLINE, MEDLINE Epub Ahead of Print & MEDLINE In-Process, PsychINFO, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Science Citation Index (SCI), Cochrane Central Register of Controlled Trials (CENTRAL), and ClinicalTrials.gov. Ovid MEDLINE and EMBASE autoalerts have been in place since 2002 and results are screened regularly for long-term RCTs on obesity management in adults (≥ 1 year of follow-up). Copies of relevant reports are retained and the reviewers hand-searched these reports eligible studies. Therefore, search strategies for MEDLINE and EMBASE excluded the results of the autoalert search (using the Boolean operator NOT). A supplementary search of MEDLINE was undertaken to identify systematic reviews of severe or morbid obesity, and reference lists were scrutinised for additional studies.

RCTs for Review 1 (weight loss or weight maintenance programmes for adults with obesity and Review 5 (weight loss or weight maintenance programmes for adults with obesity compared with bariatric surgery)

MEDLINE and EMBASE

Ovid multifile search: <http://shibboleth.ovid.com/>

Database: Embase <1988 to 2017 Week 17>, Ovid MEDLINE(R) Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) <1946 to Present> 25th April 2017

Date of Search: 25th April 2017

- 1 Obesity, Morbid/dh, dt, su, th use ppez
- 2 Morbid Obesity/dt, su, th use emed
- 3 Obesity, Morbid/ use ppez
- 4 Morbid Obesity/ use emed
- 5 (obes\$ adj3 (morbid\$ or severe\$)).tw.
- 6 (morbid obesity or severe obesity).kw.
- 7 (bmi adj ("27\$" or "28\$" or "29\$")).tw.
- 8 (bmi adj ("30\$" or "31\$" or "32\$" or "33\$" or "34\$" or "35\$" or "36\$" or "37\$" or "38\$" or "39\$")).tw.
- 9 (bmi adj ("40\$" or "41\$" or "42\$" or "43\$" or "44\$" or "45\$" or "46\$" or "47\$" or "48\$" or "49\$")).tw.
- 10 (bmi adj ("50\$" or "51\$" or "52\$" or "53\$" or "54\$" or "55\$")).tw.
- 11 (body mass index adj ("35\$" or "36\$" or "37\$" or "38\$" or "39\$")).tw.
- 12 (body mass index adj ("40\$" or "41\$" or "42\$" or "43\$" or "44\$" or "45\$" or "46\$" or "47\$" or "48\$" or "49\$")).tw.
- 13 (body mass index adj ("50\$" or "51\$" or "52\$" or "53\$" or "54\$" or "55\$")).tw.
- 14 or/3-12
- 15 exp bariatric surgery/
- 16 bariatric.tw,kw.

- 17 (gastric adj3 (bypass or bypass or band\$ or balloon\$)).tw.
- 18 (gastroplast\$ or gastrect\$).tw.
- 19 (jejunoileal adj3 (bypass or by pass)).tw.
- 20 lipectom\$.tw
- 21 diet therapy/ use ppez or caloric restriction/ use ppez or diet, carbohydrate-restricted/ use ppez or diet, fat-restricted/ use ppez or diet, reducing/ use ppez
- 22 diet/ use emed or low calory diet/ use emed or low carbohydrate diet/ use emed
- 23 (diet adj3 (restrict\$ or reduc\$ or modif\$ or calorie\$)).tw.
- 24 (calori\$ adj3 (reduc\$ or restrict\$ or limit\$)).tw.
- 25 exp anti-obesity agents/ use ppez
- 26 tetrahydrolipstatin/ use emed
- 27 sibutramine/ use emed
- 28 rimonabant/ use emed
- 29 (appetite adj3 (reduc\$ or depress\$)).tw.
- 30 (orlistat or xenical).tw,rn.
- 31 (sibutramin\$ or arcalion or reductil or medaria or meridia).tw,rn.
- 32 (rimonabant or acomplia or zimulti).tw,rn.
- 33 exp exercise/
- 34 exp sports/
- 35 (exercise or aerobic or physical activ\$).tw.
- 36 weight loss/ use ppez
- 37 weight reduction/ use emed
- 38 (weight adj3 (reduc\$ or loss or lose)).tw.
- 39 Weight Reduction Programs/ use ppez
- 40 exp Body Weight Management/ use emed
- 41 Behavior Therapy/
- 42 Health Education/
- 43 Counseling/ use ppez
- 44 Nutritional counseling/ use emed
- 45 Life Style/ use ppez
- 46 Lifestyle modification/ use emed
- 47 (modif\$ adj3 (behavio?r or diet or eat? or eating)).tw.
- 48 ((diet or weight) adj3 (educat\$ or counsel\$)).tw.

49 or/15-46
50 1 or 2 or (14 and 49)
51 randomized controlled trial.pt.
52 controlled clinical trial.pt
53 randomi?ed.ab.
54 placebo.ab.
55 drug therapy.fs.
56 randomly.ab.
57 trial.ab.
58 groups.ab
59 nonhuman/ not human/
60 exp clinical trial/ use emed
61 randomization/ use emed
62 51 or 52 or 53 or 54 or 55 or 56 or 57 or 58 or 60 or 61
63 exp animals/ use ppez not humans/ use ppez
64 nonhuman/ use emed or animal/ use emed
65 64 not exp human/ use emed
66 62 not (63 or 65)
67 50 and 66
68 67 not (abstract or letter or note or editorial or comment).pt.
69 limit 68 to yr="1990 -Current"
70 obesity/
71 (obesity adj2 (morbid or diabet\$)).tw.
72 obesity, morbid/ use ppez
73 morbid obesity/ use emed
74 obes\$.tw.
75 weight loss/ use ppez
76 weight reduction/ use emed
77 (weight adj1 (los\$ or reduc\$ or maint\$ or control)).tw.
78 (diet adj5 weight).tw.
79 overweight.tw.
80 or/70-79
81 80 and 66

82 69 not 81

PsycINFO

Ovid: <http://shibboleth.ovid.com/>

Database: PsycINFO <1987 to April Week 3 2017>

Date of Search: 25th April 2017

1 (obes\$ adj3 (morbid\$ or severe\$)).tw.

2 (bmi adj ("27\$" or "28\$" or "29\$")).tw.

3 (bmi adj ("30\$" or "31\$" or "32\$" or "33\$" or "34\$" or "35\$" or "36\$" or "37\$" or "38\$" or "39\$")).tw.

4 (bmi adj ("40\$" or "41\$" or "42\$" or "43\$" or "44\$" or "45\$" or "46\$" or "47\$" or "48\$" or "49\$")).tw.

5 (bmi adj ("50\$" or "51\$" or "52\$" or "53\$" or "54\$" or "55\$")).tw. (

6 (body mass index adj ("27\$" or "28\$" or "29\$")).tw.

7 (body mass index adj ("30\$" or "31\$" or "32\$" or "33\$" or "34\$" or "35\$" or "36\$" or "37\$" or "38\$" or "39\$")).tw.

8 (body mass index adj ("40\$" or "41\$" or "42\$" or "43\$" or "44\$" or "45\$" or "46\$" or "47\$" or "48\$" or "49\$")).tw.

9 (body mass index adj ("50\$" or "51\$" or "52\$" or "53\$" or "54\$" or "55\$")).tw. (7)

10 or/1-9

11 clinical trials/

12 randomi?ed.tw,md.

13 randomly.tw,md.

14 trial?.tw,md

15 or/11-14

16 10 and 15

CINAHL

<http://search.ebscohost.com>

!990- 25th April 2017

Date of Search: 25th April 2017

S1 (MH "Obesity, Morbid") OR TX (obes|* N3 (morbid or sever*))
S2 TX (bmi N3 (27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39).) OR TX (bmi N3 (40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49).) OR TX (bmi N3 (50 or 51 or 52 or 53 or 54 or 55).)
S3 TX (body mass index N3 (35 or 36 or 37 or 38 or 39).) OR TX (body mass index N3 (40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49).) OR TX (body mass index N3 (50 or 51 or 52 or 53 or 54 or 55).)
S4 S1 OR S2 OR S3
S5 (MH "Bariatric Surgery+")
S6 TX bariatric OR TX gastroplasty
S7 TX bariatric OR TX gastroplast* AND TX gastrect*
S8 TX (gastric N3 (by pass or by pass or band* or balloon*)) OR TX (jejunoileal N3 (bypass or by pass) OR TX lipectom*
S9 (MH "Diet Therapy") OR (MH "Diet, Reducing") OR (MH "Restricted Diet") OR (MH "Diet, Fat-Restricted") OR (MH "Diet, Low Carbohydrate")
S10 TX (diet N3 (restrict* or reduc* or modif* or calorie*)) OR TX (calori* N3 (reduc* or restrict* or limit*).)
S11 (MH "Antiobesity Agents+")
S12 TX (orlistat or xenical) OR TX (sibutramin\$ or arcalion or reductil or medaria or meridia) OR TX (rimonabant or acomplia or zimulti)
S13 (MH "Exercise+")
S14 TX exercise or aerobic or physical activ*.
S15 (MH "Physical Fitness")
S16 (MH "Weight Loss")
S17 TX weight N3 (reduc* or loss or lose)).
S18 (MH "Weight Reduction Programs")
S19 (MH "Counseling")
S20 (MH "Life Style") OR (MH "Life Style Changes")
S21 TX (modif* N3 (behavior or behaviour or diet or eat* or eating) OR TX ((diet or weight) N3 (educat* or counsel*).)

S22 S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14 OR S15 OR S16
OR S17 OR S18 OR S19 OR S21

S23 S4 AND S22 Limiters - Published Date: 19900101-20161231

S24 S4 AND S22 Limiters - Exclude MEDLINE records

Science Citation Index

www.webofknowledge.com

1988 - 25th April 2017

Date of Search: 25th April 2017

1 (TS=(morbid NEAR/3 obes\$)) AND DOCUMENT TYPES: (Article)

2 (TS=(severe\$ NEAR/3 obes\$)) AND DOCUMENT TYPES: (Article)

3 (TS=(bmi NEAR/3 (27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39))) AND DOCUMENT TYPES: (Article)

4 ((TS=(bmi NEAR/3 (40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49)))) AND DOCUMENT TYPES: (Article)

5 ((TS=(bmi NEAR/3 (50 or 51 or 52 or 53 or 54 or 55)))) AND DOCUMENT TYPES: (Article)

6 #5 OR #4 OR #3 OR #2 OR #1

7 (TS=(randomized or randomised or randomly)) AND DOCUMENT TYPES: (Article)

8 (TS=clinical trial*) AND DOCUMENT TYPES: (Article)

9 #8 OR #7

10 #9 AND #6

11 (TS=(bariatric or gastroplast* or gastrect*)) AND DOCUMENT TYPES: (Article)

12 (TS=((gastric or jejunoileal) NEAR/3 bypass)) AND DOCUMENT TYPES: (Article)

13 ((TS=((gastric or jejunoileal) NEAR/3 "by pass"))) AND DOCUMENT TYPES: (Article)

14 (TS=(gastric NEAR/3 (band* or balloon*))) AND DOCUMENT TYPES: (Article)

15 (TS=(diet NEAR/3 (restrict* or reduc* or modif* or calorie*))) AND DOCUMENT TYPES: (Article)
16 (TS=(calori* NEAR/3 (reduc* or restrict* or limit*))) AND DOCUMENT TYPES: (Article)
17 (TS=(appetite NEAR/3 (reduc* or depress*))) AND DOCUMENT TYPES: (Article)
18 (TS=(orlistat or xenical)) AND DOCUMENT TYPES: (Article)
19 (TS=(sibutramin or arcalion or reductil or medaria or meridia)) AND DOCUMENT TYPES: (Article)
20 (TS=(rimonabant or acomplia or zimulti)) AND DOCUMENT TYPES: (Article)
21 (TS=(exercise or aerobic or physical active*)) AND DOCUMENT TYPES: (Article)
22 (TS=(weight NEAR/3 (reduc* or loss or lose))) AND DOCUMENT TYPES: (Article)
23 (TS=(modif* NEAR/3 (behavior or behaviour or diet or eat? or eating))) AND DOCUMENT TYPES: (Article)
24 (TS=(diet NEAR/3 (educat* or counsel*))) AND DOCUMENT TYPES: (Article)
25 (TS=(weight NEAR/3 (educat* or counsel*))) AND DOCUMENT TYPES: (Article)
26 #25 OR #24 OR #23 OR #22 OR #21 OR #20 OR #19 OR #18 OR #17 OR #16 OR #15 OR #14 OR #13 OR #12 OR #11
#27 #10 AND #26

Cochrane Central Register of Controlled Trials

www.thecochranelibrary.com

Issue 4 April 2017


Date of Search: 25th April 2017

#1 MeSH descriptor: [Obesity, Morbid] explode all trees and with qualifier(s): [Diet therapy - DH, Surgery - SU, Therapy - TH]

- #2 MeSH descriptor: [Obesity, Morbid] explode all trees
- #3 obes* near/3 (morbid* or severe*):ti,ab,kw (Word variations have been searched)
- #4 bmi near/1 (27* or 28* or 29* or 30* or 31* or 32* or 33* or 34* or 35* or 36* or 37* or 38* or 39*):ti,ab,kw or bmi near/1 (40* or 41* or 42* or 43* or 44* or 45* or 46* or 47* or 48* or 49*):ti,ab,kw or bmi near/1 (50* or 51* or 52* or 53* or 54* or 55*):ti,ab,kw (Word variations have been searched)
- #5 body mass index near/1 (27* or 28* or 29* or 30* or 31* or 32* or 33* or 34* or 35* or 36* or 37* or 38* or 39*):ti,ab,kw or body mass index near/1 (40* or 41* or 42* or 43* or 44* or 45* or 46* or 47* or 48* or 49*):ti,ab,kw or body mass index near/1 (50* or 51* or 52* or 53* or 54* or 55*):ti,ab,kw (Word variations have been searched)
- #6 #2 or #3 or #4 or #5
- #7 MeSH descriptor: [Bariatric Surgery] explode all trees
- #8 bariatric:ti,ab,kw (Word variations have been searched)
- #9 gastric near/3 (bypass or by pass or band* or balloon*):ti,ab,kw or gastroplast* or gastrect*:ti,ab,kw or lipectom*:ti,ab,kw or jejunoileal near/3 (bypass or by pass):ti,ab,kw (Word variations have been searched)
- #10 MeSH descriptor: [Diet Therapy] explode all trees
- #11 MeSH descriptor: [Diet, Reducing] explode all trees
- #12 MeSH descriptor: [Diet, Fat-Restricted] explode all trees
- #13 MeSH descriptor: [Diet, Carbohydrate-Restricted] explode all trees
- #14 MeSH descriptor: [Caloric Restriction] explode all trees
- #15 diet near/3 (restrict* or reduc* or modif* or calorie*):ti,ab,kw or kalori* near/3 (reduc* or restrict* or limit*):ti,ab,kw (Word variations have been searched)
- #16 MeSH descriptor: [Anti-Obesity Agents] explode all trees
- #17 appetite near/3 (reduc* or depress*):ti,ab,kw or orlistat or xenical:ti,ab,kw or sibutramin or arcalion or reductil or medaria or meridia:ti,ab,kw or rimonabant or acomplia or zimulti:ti,ab,kw (Word variations have been searched)
- #18 MeSH descriptor: [Exercise] explode all trees
- #19 MeSH descriptor: [Sports] explode all trees
- #20 exercise or aerobic* or physical activ*:ti,ab,kw (Word variations have been searched)

- #21 MeSH descriptor: [Weight Loss] explode all trees
- #22 MeSH descriptor: [Weight Reduction Programs] explode all trees
- #23 weight near/3 (reduc* or loss or lose) .:ti,ab,kw (Word variations have been searched)
- #24 weight near/3 (reduc* or loss or lose) .:ti,ab,kw (Word variations have been searched)
- #25 MeSH descriptor: [Behavior Therapy] explode all trees
- #26 MeSH descriptor: [Health Education] explode all trees
- #27 MeSH descriptor: [Counseling] explode all trees
- #28 MeSH descriptor: [Life Style] explode all trees
- #29 diet near/3 (educat* or counsel*):ti,ab,kw or modif* near/3 (behaviour or behavior or diet or eat or eating):ti,ab,kw or weight near/3 (educat* or counsel*):ti,ab,kw (Word variations have been searched)
- #30 #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29
- #31 #6 and #30
- #32 #1 or #31 Publication Year from 1990 to 2016, in Trials
- #33 conference abstract (Word variations have been searched)
- #34 #32 not #33

Appendix 2 PRISMA flow diagram



Appendix 3 List of included studies

Agras WS, Berkowitz RI, Arnow BA, Telch CF, Marnell M, Henderson J, et al. Maintenance following a very-low-calorie diet. *Journal of Consulting & Clinical Psychology* 1996;**64**:610-3.

Annesi JJ. Mediation of the relationship of behavioural treatment type and changes in psychological predictors of healthy eating by body satisfaction changes in women with obesity. *Obesity Research & Clinical Practice* 2017;**11**:97-107.

Appel LJ, Clark JM, Yeh HC, Wang NY, Coughlin JW, Daumit G, et al. Comparative effectiveness of weight-loss interventions in clinical practice. *New England Journal of Medicine* 2011;**365**:1959-68.

Azar KM, Xiao L, Ma J. Baseline obesity status modifies effectiveness of adapted diabetes prevention program lifestyle interventions for weight management in primary care. *BioMed Research International* 2013;191209.

Bacon L, Keim NL, Van Loan MD, Derricote M, Gale B, Kazaks A, et al. Evaluating a 'non-diet' wellness intervention for improvement of metabolic fitness, psychological well-being and eating and activity behaviors. *International Journal of Obesity & Related Metabolic Disorders* 2002;**26**:854-65.

Bakris G, Calhoun D, Egan B, Hellmann C, Dolker M, Kingma I. Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. *Journal of Hypertension* 2002;**20**:2257-67.

Bartels SJ, Pratt SI, Aschbrenner KA, Barre LK, Jue K, Wolfe RS, et al. Clinically Significant Improved Fitness and Weight Loss Among Overweight Persons With Serious Mental Illness. *Psychiatric Services* 2013;**64**:729-36.

Bartels SJ, Pratt SI, Aschbrenner KA, Barre LK, Naslund JA, Wolfe R, et al. Pragmatic Replication Trial of Health Promotion Coaching for Obesity in Serious Mental Illness and Maintenance of Outcomes. *American Journal of Psychiatry* 2015;**172**:344-52.

Bazzano LA, Hu T, Reynolds K, Yao L, Bunol C, Liu Y, et al. Effects of low-carbohydrate and low-fat diets: a randomized trial. *Annals of Internal Medicine* 2014;**161**:309-18.

Bennett GG, Warner ET, Glasgow RE, Askew S, Goldman J, Ritzwoller DP, et al. Obesity treatment for socioeconomically disadvantaged patients in primary care practice. *Archives of Internal Medicine* 2012;**172**:565-74.

Berry DC, Schwartz TA, McMurray RG, Skelly AH, Neal M, Hall EG, et al. The family partners for health study: a cluster randomized controlled trial for child and parent weight management. *Nutrition & Diabetes* 2014;**4**:e101.

- Berteus Forslund H, Klingstrom S, Hagberg H, Londahl M, Torgerson JS, Lindroos AK. Should snacks be recommended in obesity treatment? A 1-year randomized clinical trial. *European Journal of Clinical Nutrition* 2008;**62**:1308-17.
- Beutel ME, Dippel A, Szczepanski M, Thiede R, Wiltink J. Mid-term effectiveness of behavioral and psychodynamic inpatient treatments of severe obesity based on a randomized study. *Psychotherapy and Psychosomatics* 2006;**75**:337-45.
- Bliddal H, Leeds AR, Stigsgaard L, Astrup A, Christensen R. Weight loss as treatment for knee osteoarthritis symptoms in obese patients: 1-Year results from a randomised controlled trial. *Annals of the Rheumatic Diseases* 2011;**70**:1798-803.
- Brehm BJ, Lattin BL, Summer SS, Boback JA, Gilchrist GM, Jandacek RJ, et al. One-year comparison of a high-monounsaturated fat diet with a high-carbohydrate diet in type 2 diabetes. *Diabetes Care* 2009;**32**:215-20.
- Broom I, Hughes E, Dodson P, Reckless J. The role of orlistat in the treatment of obese patients with mild to moderate hypercholesterolaemia: Consequences for coronary risk. *British Journal of Cardiology* 2002;**9**:460-1+8.
- Broom I, Wilding J, Stott P, Myers N. Randomised trial of the effect of orlistat on body weight and cardiovascular disease risk profile in obese patients: UK multimorbidity study. *International Journal of Clinical Practice* 2002;**56**:494-9.
- Burguera B, Jesus Tur J, Escudero AJ, Alos M, Pagan A, Cortes B, et al. An Intensive Lifestyle Intervention Is an Effective Treatment of Morbid Obesity: The TRAMOMTANA Study-A Two-Year Randomized Controlled Clinical Trial. *International journal of endocrinology* 2015.
- Cheskin LJ, Mitchell AM, Jhaveri AD, Mitola AH, Davis LM, Lewis RA, et al. Efficacy of meal replacements versus a standard food-based diet for weight loss in type 2 diabetes: a controlled clinical trial. *Diabetes Educator* 2008;**34**:118-27.
- Christensen P, Frederiksen R, Bliddal H, Riecke BF, Bartels EM, Henriksen M, et al. Comparison of three weight maintenance programs on cardiovascular risk, bone and vitamins in sedentary older adults. *Obesity* 2013;**21**:1982-90.
- Courcoulas AP, Goodpaster BH, Eagleton JK, Belle SH, Kalarchian MA, Lang W, et al. Surgical vs medical treatments for type 2 diabetes mellitus: a randomized clinical trial. *JAMA Surgery* 2014;**149**:707-15.
- Cummings DE, Arterburn DE, Westbrook EO, Kuzma JN, Stewart SD, Chan CP, et al. Gastric bypass surgery vs intensive lifestyle and medical intervention for type 2 diabetes: the CROSSROADS randomised controlled trial. *Diabetologia* 2016;**59**:945-53.

- Dalle Grave R, Calugi S, Gavasso I, El Ghoch M, Marchesini G. A randomized trial of energy-restricted high-protein versus high-carbohydrate, low-fat diet in morbid obesity. *Obesity* 2013;**21**:1774-81.
- Damschroder LJ, Lutes LD, Kirsh S, Kim HM, Gillon L, Holleman RG, et al. Small-changes obesity treatment among veterans: 12-month outcomes. *American Journal of Preventive Medicine* 2014;**47**:541-53.
- Daubenmier J, Moran PJ, Kristeller J, Acree M, Bacchetti P, Kemeny ME, et al. Effects of a mindfulness-based weight loss intervention in adults with obesity: A randomized clinical trial. *Obesity* 2016;**24**:794-804.
- Daumit GL, Dickerson FB, Wang NY, Dalcin A, Jerome GJ, Anderson CAM, et al. A behavioral weight-loss intervention in persons with serious mental illness. *New England Journal of Medicine* 2013;**368**:1594-602.
- Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: A randomized controlled trial. *Journal of the American Medical Association* 1999;**281**:235-42.
- Davis NJ, Tomuta N, Schechter C, Isasi CR, Segal-Isaacson CJ, Stein D, et al. Comparative study of the effects of a 1-year dietary intervention of a low-carbohydrate diet versus a low-fat diet on weight and glycemic control in type 2 diabetes. *Diabetes Care* 2009;**32**:1147-52.
- Delbridge EA, Prendergast LA, Pritchard JE, Proietto J. One-year weight maintenance after significant weight loss in healthy overweight and obese subjects: Does diet composition matter? *American Journal of Clinical Nutrition* 2009;**90**:1203-14.
- Dennison KF, Galante D, Dennison D, Golaszewski T. A one year post-program assessment of a computer-assisted instruction weight management program for industrial employees: lessons learned. *Journal of Health Education* 1996;**27**:38-43.
- Dixon JB, O'Brien PE, Playfair J, Chapman L, Schachter LM, Skinner S, et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. *JAMA* 2008;**299**:316-23.
- Dixon JB, Schachter LM, O'Brien PE, Jones K, Grima M, Lambert G, et al. Surgical vs conventional therapy for weight loss treatment of obstructive sleep apnea: A randomized controlled trial. *JAMA* 2012;**308**:1142-9.
- Djuric Z, Mirasolo J, Kimbrough L, Brown DR, Heilbrun LK, Canar L, et al. A pilot trial of spirituality counseling for weight loss maintenance in African American breast cancer survivors. *Journal of the National Medical Association* 2009;**101**:552-64.

Dutton GR, Nackers LM, Dubyak PJ, Rushing NC, Huynh TVT, Tan F, et al. A randomized trial comparing weight loss treatment delivered in large versus small groups. *International Journal of Behavioral Nutrition and Physical Activity* 2014;**11** (1)

Eaton CB, Hartman SJ, Perzanowski E, Pan GH, Roberts MB, Risica PM, et al. A Randomized Clinical Trial of a Tailored Lifestyle Intervention for Obese, Sedentary, Primary Care Patients. *Annals of Family Medicine* 2016;**14**:311-9.

Ebbeling CB, Leidig MM, Feldman HA, Lovesky MM, Ludwig DS. Effects of a low-glycemic load vs low-fat diet in obese young adults: A randomized trial. *Journal of the American Medical Association* 2007;**297**:2092-102.

Esposito K, Giugliano F, Di Palo C, Giugliano G, Marfella R, D'Andrea F, et al. Effect of lifestyle changes on erectile dysfunction in obese men: A randomized controlled trial. *Journal of the American Medical Association* 2004;**291**:2978-84.

Finer N, James WPT, Kopelman PG, Lean MEJ, Williams G. One-year treatment of obesity: A randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. *International Journal of Obesity* 2000;**24**:306-13.

Fitzgibbon ML, Stolley MR, Schiffer L, Sharp LK, Singh V, Dyer A. Obesity reduction black intervention trial (ORBIT): 18-month results. *Obesity* 2010;**18**:2317-25.

Flechtner-Mors M, Boehm BO, Wittmann R, Thoma U, Ditschuneit HH. Enhanced weight loss with protein-enriched meal replacements in subjects with the metabolic syndrome. *Diabetes/Metabolism Research and Reviews* 2010;**26**:393-405.

Foster GD, Wyatt HR, Hill JO, Makris AP, Rosenbaum DL, Brill C, et al. Weight and metabolic outcomes after 2 years on a low-carbohydrate versus low-fat diet: A randomized trial. *Annals of Internal Medicine* 2010;**153**:147-57.

Goodpaster BH, Delany JP, Otto AD, Kuller L, Vockley J, South-Paul JE, et al. Effects of diet and physical activity interventions on weight loss and cardiometabolic risk factors in severely obese adults: a randomized trial. *JAMA* 2010;**304**:1795-802.

Gorin AA, Raynor HA, Fava J, Maguire K, Robichaud E, Trautvetter J, et al. Randomized controlled trial of a comprehensive home environment-focused weight-loss program for adults. *Health Psychology* 2013;**32**:128-37.

Green CA, Yarborough BJH, Leo MC, Stumbo SP, Perrin NA, Nichols GA, et al. Weight maintenance following the STRIDE lifestyle intervention for individuals taking antipsychotic medications. *Obesity* 2015;**23**:1995-2001.

Hakala P, Karvetti RL, Rönnemaa T. Group vs. individual weight reduction programmes in the treatment of severe obesity--a five year follow-up study. *International journal of obesity and related metabolic disorders* 1993;**17**:97-102.

Hakala P. Weight reduction programmes at a rehabilitation centre and a health centre based on group counselling and individual support: Short- and long-term follow-up study. *International Journal of Obesity* 1994;**18**:483-9.

Hauptman J, Lucas C, Boldrin MN, Collins H, Segal KR. Orlistat in the long-term treatment of obesity in primary care settings. *Archives of Family Medicine* 2000;**9**:160-7.

Hunt K, Wyke S, Gray CM, Anderson AS, Brady A, Bunn C, et al. A gender-sensitised weight loss and healthy living programme for overweight and obese men delivered by Scottish Premier League football clubs (FFIT): A pragmatic randomised controlled trial. *The Lancet* 2014;**383**:1211-21.

Iqbal N, Vetter ML, Moore RH, Chittams JL, Dalton-Bakes CV, Dowd M, et al. Effects of a low-intensity intervention that prescribed a low-carbohydrate vs. a low-fat diet in obese, diabetic participants. *Obesity* 2010;**18**:1733-8.

Jesudason DR, Pedersen E, Clifton PM. Weight-loss diets in people with type 2 diabetes and renal disease: a randomized controlled trial of the effect of different dietary protein amounts. *American Journal of Clinical Nutrition* 2013;**98**:494-501.

Kahleova H, Hill M, Pelikanova T. Vegetarian vs. conventional diabetic diet - A 1-year follow-up. *Cor et Vasa* 2014;**56**:e140-e4.

Kelley DE, Bray GA, Pi-Sunyer FX, Klein S, Hill J, Miles J, et al. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial. *Diabetes Care* 2002;**25**:1033-41.

Keranen AM, Savolainen MJ, Reponen AH, Kujari ML, Lindeman SM, Bloigu RS, et al. The effect of eating behavior on weight loss and maintenance during a lifestyle intervention. *Preventive Medicine* 2009;**49**:32-8.

Khoo J, Piantadosi C, Duncan R, Worthley SG, Jenkins A, Noakes M, et al. Comparing effects of a low-energy diet and a high-protein low-fat diet on sexual and endothelial function, urinary tract symptoms, and inflammation in obese diabetic men. *Journal of Sexual Medicine* 2011;**8**:2868-75.

Krebs JD, Elley CR, Parry-Strong A, Lunt H, Drury PL, Bell DA, et al. The Diabetes Excess Weight Loss (DEWL) Trial: A randomised controlled trial of high-protein versus high-carbohydrate diets over 2 years in type 2 diabetes. *Diabetologia* 2012;**55**:905-14.

Krempf M, Louvet JP, Allanic H, Miloradovich T, Joubert JM, Attali JR. Weight reduction and long-term maintenance after 18 months treatment with orlistat for obesity. *International Journal of Obesity* 2003;**27**:591-7.

Kumanyika SK, Fassbender JE, Sarwer DB, Phipps E, Allison KC, Localio R, et al. One-year results of the think health study of weight management in primary care practices. *Obesity* 2012;**20**:1249-57.

Kumanyika SK, Shults J, Fassbender J, Whitt MC, Brake V, Kallan MJ, et al. Outpatient weight management in African-Americans: The Healthy Eating and Lifestyle Program (HELP) study. *Preventive Medicine* 2005;**41**:488-502.

Kumanyika SK, Wadden TA, Shults J, Fassbender JE, Brown SD, Bowman MA, et al. Trial of family and friend support for weight loss in African American adults. *Archives of Internal Medicine* 2009;**169**:1795-804.

Lantz H, Peltonen M, Agren L, Torgerson JS. Intermittent versus on-demand use of a very low calorie diet: A randomized 2-year clinical trial. *Journal of Internal Medicine* 2003;**253**:463-71.

Latner JD, Ciao AC, Wendicke AU, Murakami JM, Durso LE. Community-based behavioral weight-loss treatment: Long-term maintenance of weight loss, physiological, and psychological outcomes. *Behaviour Research and Therapy* 2013;**51**:451-9.

Lillis J, Niemeier HM, Thomas JG, Unick J, Ross KM, Leahey TM, et al. A Randomized Trial of an Acceptance-Based Behavioral Intervention for Weight Loss in People with High Internal Disinhibition. *Obesity* 2016;**24**:2509-14.

Linde JA, Simon GE, Ludman EJ, Ichikawa LE, Operskalski BH, Arterburn D, et al. A randomized controlled trial of behavioral weight loss treatment versus combined weight loss/depression treatment among women with comorbid obesity and depression. *Annals of behavioral medicine* 2011;**41**:119-30.

Little P, Stuart B, Hobbs FR, Kelly J, Smith ER, Bradbury KJ, et al. An internet-based intervention with brief nurse support to manage obesity in primary care (POWeR+): a pragmatic, parallel-group, randomised controlled trial. *The Lancet Diabetes and Endocrinology* 2016;**4**:821-8.

Look Ahead Research Group, Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes.[Erratum appears in N Engl J Med. 2014 May 8;370(19):1866]. *New England Journal of Medicine* 2013;**369**:145-54.

Lowe MR, Butryn ML, Thomas JG, Coletta M. Meal replacements, reduced energy density eating, and weight loss maintenance in primary care patients: a randomized controlled trial. *Obesity* 2014;**22**:94-100.

Ma J, Strub P, Xiao L, Lavori PW, Camargo CA, Jr., Wilson SR, et al. Behavioral weight loss and physical activity intervention in obese adults with asthma. A randomized trial. *Annals of the American Thoracic Society* 2015;**12**:1-11.

Maclaughlin HL, Hall WL, Patel AG, Blacklock RM, Swift PA, Phanish MK, et al. Weight loss, adipokines, and quality of life after sleeve gastrectomy in obese patients with stages 3-4 CKD: A randomized controlled pilot study. *American Journal of Kidney Diseases* 2014;**64**:660-3.

Manzoni GM, Cesa GL, Bacchetta M, Castelnuovo G, Conti S, Gaggioli A, et al. Virtual reality-enhanced cognitive-behavioral therapy for morbid obesity: A randomized controlled study with 1 year follow-up. *Cyberpsychology, Behavior, and Social Networking* 2016;**19**:134-40.

Martin PD, Dutton GR, Rhode PC, Horswell RL, Ryan DH, Brantley PJ. Weight loss maintenance following a primary care intervention for low-income minority women. *Obesity* 2008;**16**:2462-7.

Mayer-Davis EJ, D'Antonio AM, Smith SM, Kirkner G, Martin SL, Parra-Medina D, et al. Pounds off with empowerment (POWER): A clinical trial of weight management strategies for black and white adults with diabetes who live in medically underserved rural communities. *American Journal of Public Health* 2004;**94**:1736-42.

McRobbie H, Hajek P, Peerbux S, Kahan BC, Eldridge S, Trepel D, et al. Tackling obesity in areas of high social deprivation: clinical effectiveness and cost-effectiveness of a task-based weight management group programme - a randomised controlled trial and economic evaluation. *Health Technology Assessment* 2016;**20(79)**..

Melin I, Karlstrom B, Lappalainen R, Berglund L, Mohsen R, Vessby B. A programme of behaviour modification and nutrition counselling in the treatment of obesity: A randomised 2-y clinical trial. *International Journal of Obesity* 2003;**27**:1127-35.

Mensinger JL, Calogero RM, Stranges S, Tylka TL. A weight-neutral versus weight-loss approach for health promotion in women with high BMI: A randomized-controlled trial. *Appetite* 2016;**105**:364-74.

Miles JM, Leiter L, Hollander P, Wadden T, Anderson JW, Doyle M, et al. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. *Diabetes Care* 2002;**25**:1123-8.

Mingrone G, Greco AV, Giancaterini A, Scarfone A, Castagneto M, Pugeat M. Sex hormone-binding globulin levels and cardiovascular risk factors in morbidly obese subjects before and after weight reduction induced by diet or malabsorptive surgery. *Atherosclerosis* 2002;**161**:455-62.

Mingrone G, Panunzi S, De Gaetano A, Guidone C, Iaconelli A, Leccesi L, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. *New England Journal of Medicine* 2012;**366**:1577-85.

Moreno B, Bellido D, Sajoux I, Goday A, Saavedra D, Crujeiras AB, et al. Comparison of a very low-calorie-ketogenic diet with a standard low-calorie diet in the treatment of obesity. *Endocrine* 2014;**47**:793-805.

Nackers LM, Middleton KR, Dubyak PJ, Daniels MJ, Anton SD, Perri MG. Effects of prescribing 1,000 versus 1,500 kilocalories per day in the behavioral treatment of obesity: A randomized trial. *Obesity* 2013;**21**:2481-7.

Nilsen V, Bakke PS, Gallefoss F. Effects of lifestyle intervention in persons at risk for type 2 diabetes mellitus - results from a randomised, controlled trial. *BMC public health* 2011;**11**:893.

O'Neil PM, Miller-Kovach K, Tuerk PW, Becker LE, Wadden TA, Fujioka K, et al. Randomized Controlled Trial of a Nationally Available Weight Control Program Tailored for Adults with Type 2 Diabetes. *Obesity* 2016;**24**:2269-77.

Ostbye T, Stroo M, Brouwer RJ, Peterson BL, Eisenstein EL, Fuemmeler BF, et al. Steps to Health employee weight management randomized Control trial: Short-term follow-up results. *Journal of Occupational and Environmental Medicine* 2015;**57**:188-95.

Pascale RW, Wing RR, Butler BA, Mullen M, Bononi P. Effects of a behavioral weight loss program stressing calorie restriction versus calorie plus fat restriction in obese individuals with NIDDM or a family history of diabetes. *Diabetes Care* 1995;**18**:1241-8.

Pedersen E, Jesudason DR, Clifton PM. High protein weight loss diets in obese subjects with type 2 diabetes mellitus. *Nutrition, Metabolism and Cardiovascular Diseases* 2014;**24**:554-62.

Pekkarinen T, Kaukua J, Mustajoki P. Long-term weight maintenance after a 17-week weight loss intervention with or without a one-year maintenance program: A randomized controlled trial. *Journal of Obesity* 2015;Article 651460

Perri MG, Limacher MC, Durning PE, Janicke DM, Lutes LD, Bobroff LB, et al. Extended-care programs for weight management in rural communities: The Treatment of Obesity in Underserved Rural Settings (TOURS) randomized trial. *Archives of Internal Medicine* 2008;**168**:2347-54.

Perri MG, Limacher MC, Von Castel-Roberts K, Daniels MJ, Durning PE, Janicke DM, et al. Comparative effectiveness of three doses of weight-loss counseling: Two-year findings from the Rural LITE Trial. *Obesity* 2014;**22**:2293-300.

Perri MG, Nezu AM, McKelvey WF, Shermer RL, Renjilian DA, Viegner BJ. Relapse prevention training and problem-solving therapy in the long-term management of obesity. *Journal of Consulting and Clinical Psychology* 2001;**69**:722-6.

Poston WS, Reeves RS, Haddock CK, Stormer S, Balasubramanyam A, Satterwhite O, et al. Weight loss in obese Mexican Americans treated for 1-year with orlistat and lifestyle modification. *International Journal of Obesity & Related Metabolic Disorders* 2003;**27**:1486-93.

Purcell K, Sumithran P, Prendergast LA, Bouniu CJ, Delbridge E, Proietto J. The effect of rate of weight loss on long-term weight management: A randomised controlled trial. *The Lancet Diabetes and Endocrinology* 2014;**2**:954-62.

Rapoport L, Clark M, Wardle J. Evaluation of a modified cognitive-behavioural programme for weight management. *International Journal of Obesity* 2000;**24**:1726-37.

Reichard A, Saunders MD, Saunders RR, Donnelly JE, Lauer E, Sullivan DK, et al. A comparison of two weight management programs for adults with mobility impairments. *Disability and Health Journal* 2015;**8**:61-9.

Reis LO, Favaro WJ, Barreiro GC, Oliveira LC, Chaim EA, Fregonesi A, et al. Erectile dysfunction and hormonal imbalance in morbidly obese male is reversed after gastric bypass surgery: a prospective randomized controlled trial. *International journal of andrology* 2010;**33**:736-44.

Richelsen B, Tonstad S, Rossner S, Toubro S, Niskanen L, Madsbad S, et al. Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: A 3-year randomized, placebo-controlled study. *Diabetes Care* 2007;**30**:27-32.

Rock CL, Flatt SW, Pakiz B, Taylor KS, Leone AF, Brelje K, et al. Weight loss, glycemic control, and cardiovascular disease risk factors in response to differential diet composition in a weight loss program in type 2 diabetes: A randomized controlled trial. *Diabetes Care* 2014;**37**:1573-80.

Rossner S, Flaten H. VLCD versus LCD in long-term treatment of obesity. *International Journal of Obesity* 1997;**21**:22-6.

Ryttig KR, Flaten H, Rossner S. Long-term effects of a very low calorie diet (Nutrilett) in obesity treatment. A prospective, randomized, comparison between VLCD and a hypocaloric diet + behavior modification and their combination. *International Journal of Obesity* 1997;**21**:574-9.

Ryttig KR, Rossner S. Weight maintenance after a very low calorie diet (VLCD) weight reduction period and the effects of VLCD supplementation. A prospective, randomized, comparative, controlled long-term trial. *Journal of Internal Medicine* 1995;**238**:299-306.

Schauer PR, Kashyap SR, Wolski K, Brethauer SA, Kirwan JP, Pothier CE, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. *New England Journal of Medicine* 2012;**366**:1567-76.

Shikany JM, Thomas AS, Beasley TM, Lewis CE, Allison DB. Randomized controlled trial of the Medifast 5 & 1 plan for weight loss. *International Journal of Obesity* 2013;**37**:1571-8.

Sjostrom L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HPF, et al.

- Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. *Lancet* 1998;**352**:167-72.
- Soenen S, Bonomi AG, Lemmens SGT, Scholte J, Thijssen MAMA, Van Berkum F, et al. Relatively high-protein or 'low-carb' energy-restricted diets for body weight loss and body weight maintenance? *Physiology and Behavior* 2012;**107**:374-80.
- Spring B, Duncan JM, Janke EA, Kozak AT, McFadden HG, Demott A, et al. Integrating technology into standard weight loss treatment a randomized controlled trial. *JAMA Internal Medicine* 2013;**173**:105-11.
- Stahre L, Hallstrom T. A short-term cognitive group treatment program gives substantial weight reduction up to 18 months from the end of treatment. A randomized controlled trial. *Eating and Weight Disorders* 2005;**10**:51-8.
- Stenius-Aarniala B, Poussa T, Kvarnstrom J, Gronlund EL, Ylikahri M, Mustajoki P. Immediate and long term effects of weight reduction in obese people with asthma: Randomised controlled study. *British Medical Journal* 2000;**320**:827-32.
- Stern L, Iqbal N, Seshadri P, Chicano KL, Daily DA, McGrory J, et al. The Effects of Low-Carbohydrate versus Conventional Weight Loss Diets in Severely Obese Adults: One-Year Follow-up of a Randomized Trial. *Annals of Internal Medicine* 2004;**140**:778-85+I-27.
- Strobl V, Knisel W, Landgraf U, Faller H. A combined planning and telephone aftercare intervention for obese patients: effects on physical activity and body weight after one year. *Journal of rehabilitation medicine* 2013;**45**:198-205.
- Swinburn BA, Carey D, Hills AP, Hooper M, Marks S, Proietto J, et al. Effect of orlistat on cardiovascular disease risk in obese adults. *Diabetes Obesity & Metabolism* 2005;**7**:254-62.
- Torgerson J, Agren L, Sjostrom L. Effects on body weight of strict or liberal adherence to an initial period of VLCD treatment. A randomised, one-year clinical trial of obese subjects. *International Journal of Obesity* 1999;**23**:190-7.
- Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study: A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. *Diabetes Care* 2004;**27**:155-61.

Torgerson JS, Lissner L, Lindroos AK, Kruijer H, Sjostrom L. VLCD plus dietary and behavioural support versus support alone in the treatment of severe obesity. A randomised two-year clinical trial. *International Journal of Obesity* 1997;**21**:987-94.

Tsai AG, Wadden TA, Rogers MA, Day SC, Moore RH, Islam BJ. A Primary Care Intervention for Weight Loss: Results of a Randomized Controlled Pilot Study. *Obesity* 2010;**18**:1614-8.

Van Name MA, Camp AW, Magenheimer EA, Li F, Dziura JD, Montosa A, et al. Effective translation of an intensive lifestyle intervention for hispanic women with prediabetes in a community health center setting. *Diabetes Care* 2016;**39**:525-31.

Villareal DT, Chode S, Parimi N, Sinacore DR, Hilton T, Armamento-Villareal R, et al. Weight loss, exercise, or both and physical function in obese older adults. *New England Journal of Medicine* 2011;**364**:1218-29.

Villareal DT, Shah K, Banks MR, Sinacore DR, Klein S. Effect of weight loss and exercise therapy on bone metabolism and mass in obese older adults: A one-year randomized controlled trial. *Journal of Clinical Endocrinology and Metabolism* 2008;**93**:2181-7.

von Gruenigen VE, Courneya KS, Gibbons HE, Kavanagh MB, Waggoner SE, Lerner E. Feasibility and effectiveness of a lifestyle intervention program in obese endometrial cancer patients: A randomized trial. *Gynecologic Oncology* 2008;**109**:19-26.

Wadden TA, Foster GD, Letizia KA. One-year behavioral treatment of obesity: Comparison of moderate and severe caloric restriction and the effects of weight maintenance therapy. *Journal of Consulting and Clinical Psychology* 1994;**62**:165-71.

Wadden TA, Berkowitz RI, Vogt RA, Steen SN, Stunkard AJ, Foster GD. Lifestyle modification in the pharmacologic treatment of obesity: a pilot investigation of a potential primary care approach. *Obesity research* 1997;**5**:218-26.

Wadden TA, Vogt RA, Foster GD, Anderson DA. Exercise and the maintenance of weight loss: 1-year follow-up of a controlled clinical trial. *Journal of Consulting and Clinical Psychology* 1998;**66**:429-33.

Wadden TA, Volger S, Sarwer DB, Vetter ML, Tsai AG, Berkowitz RI, et al. A two-year randomized trial of obesity treatment in primary care practice. *New England Journal of Medicine* 2011;**365**:1969-79.

Weinstock RS, Trief PM, Cibula D, Morin PC, Delahanty LM. Weight Loss Success in Metabolic Syndrome by Telephone Interventions: Results from the SHINE Study. *Journal of General Internal Medicine* 2013;**28**:1620-8.

West DS, DiLillo V, Bursac Z, Gore SA, Greene PG. Motivational interviewing improves weight loss in women with type 2 diabetes. *Diabetes Care* 2007;**30**:1081-7.

West DS, Gorin AA, Subak LL, Foster G, Bragg C, Hecht J, et al. A motivation-focused weight loss maintenance program is an effective alternative to a skill-based approach. *International Journal of Obesity* 2011;**35**:259-69.

Wing RR, Blair E, Marcus M, Epstein LH, Harvey J. Year-long weight loss treatment for obese patients with type II diabetes: Does including an intermittent very-low-calorie diet improve outcome? *American Journal of Medicine* 1994;**97**:354-62.

Wing RR, Marcus MD, Epstein LH, Jawad A. A "family-based" approach to the treatment of obese type II diabetic patients. *Journal of Consulting and Clinical Psychology* 1991;**59**:156-62.

Wing RR, Marcus MD, Salata R, Epstein LH, Miaskiewicz S, Blair EH. Effects of a very-low-calorie diet on long-term glycemic control in obese type 2 diabetic subjects. *Archives of Internal Medicine* 1991;**151**:1334-40.

Wing RR, Venditti E, Jakicic JM, Polley BA, Lang W. Lifestyle intervention in overweight individuals with a family history of diabetes. *Diabetes Care* 1998;**21**:350-9.

Wolf AM, Conaway MR, Crowther JQ, Hazen KY, Nadler JL, Oneida B, et al. Translating lifestyle intervention to practice in obese patients with type 2 diabetes: Improving Control with Activity and Nutrition (ICAN) study. *Diabetes Care* 2004;**27**:1570-6.

Wylie-Rosett J, Swencionis C, Ginsberg M, Cimino C, Wassertheil-Smoller S, Caban A, et al. Computerized weight loss intervention optimizes staff time: the clinical and cost results of a controlled clinical trial conducted in a managed care setting. *Journal of the American Dietetic Association* 2001;**101**:1155-62; quiz 63-64.

Yeh MC, Rodriguez E, Nawaz H, Gonzalez M, Nakamoto D, Katz DL. Technical skills for weight loss: 2-y follow-up results of a randomized trial. *International Journal of Obesity* 2003;**27**:1500-6.